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0.1  Summary 
 
Ovarian cancer currently causes ~6,000 deaths per year in Germany alone. Since only 
palliative treatment is available for ovarian carcinomas that have developed resistance against 
platinum-based chemotherapy and paclitaxel, there is a pressing medical need for the 
development of new therapeutic approaches. As survival is strongly influenced by 
immunological parameters, immunotherapeutic strategies appear promising. The research of 
our group thus aims at overcoming tumour immune escape by counteracting 
immunosuppressive mechanisms in the tumour microenvironment. 
 
In this context, we found that tumour-infiltrating myeloid-derived suppressor cells (MDSC) or 
tumour associated macrophages (TAM) which are abundant in ovarian cancer express high 
levels of the enzyme 11β-hydroxysteroid dehydrogenase1 (11-HSD1). This oxido-reductase 
enzyme is essential for the conversion of biologically inactive cortisone into active cortisol. In 
line with this observation, high endogenous cortisol levels could be detected in serum, ascitic 
fluid and tumour exudates from ovarian cancer patients. Considering that cortisol exerts 
strong anti-inflammatory and immunosuppressive effects on immune cells, it appears likely 
that high endogenous cortisol levels contribute to immune escape in ovarian cancer. We thus 
hypothesised that local activation of endogenous glucocorticoids could suppress beneficial 
immune responses in the tumour microenvironment and thereby prevent a successful 
immunotherapy. To investigate the in vivo relevance of this postulated immune escape 
mechanism, irradiated PTEN
loxP/loxP
 loxP-Stop-loxP-kras
G12D
 mice were reconstituted with 
hematopoietic stem cells from either glucocorticoid receptor (GR) expressing mice 
(GR
loxP/loxP
) or from mice with a T cell-specific glucocorticoid receptor knock-out (lck-Cre 
GR
loxP/loxP
) mice. In the host mice, the combination of a conditional PTEN knock-out with a 
latent oncogenic kras leads to tumour development when a Cre-encoding adenovirus is 
injected into the ovarian bursa. Using this model, mice that had been reconstituted with GC-
insensitive T cells showed better intratumoural T cell infiltration than control mice that had 
received functionally unaltered GR
loxP/loxP
 cells via adoptive transfer. However, tumour-
infiltrating T cells mostly assumed a Foxp3
+
 (regulatory) phenotype and survival was even 
shortened in mice with cortisol-insensitive T cells. Thus, endogenous cortisol seems to inhibit 
immune cell infiltration in ovarian cancer, but productive anti-tumour immune responses 
might still be prevented by further factors from the tumour microenvironment. 
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Thus, our data did not provide a sufficiently strong rationale to further pursue the 
antagonisation of glucocorticoid signalling in ovarian cancer patients, Moreover, 
glucocorticoids are frequently administered to cancer patients to reduce inflammation and 
swelling and to prevent chemotherapy-related toxic side effects like nausea or hypersensitivity 
reactions associated with paclitaxel therapy. Thus, we decided to address the question whether 
specific signalling pathways in innate immune cells, preferentially in NK cells, could still be 
activated even in the presence of GC. A careful investigation of the various activating NK cell 
receptors (i.e. NKp30, NKp44, NKp46), DNAM-1 and NKG2D) was thus performed which 
revealed that NKp30, NKp44 and NKG2D are all down-regulated by cortisol whereas NKp46 
is actually induced by cortisol. 
 
Interestingly, NKp46 is the only known receptor that is strictly confined to NK cells. Its 
activation via crosslinking leads to cytokine release and activation of cytotoxic activity. 
Stimulation of NK cells via NKp46 may contribute to immune-mediated tumour destruction 
by triggering the lysis of tumour cells and by altering the cytokine pattern in the tumour 
microenvironment, thereby generating more favourable conditions for the recruitment of 
antigen-specific immune cells. Accordingly, our observation that even cortisol-treated NK 
cells can still be activated via NKp46 and CD2 might become valuable for the design of 
immunotherapies that can still be applied in the presence of endogenous or therapeutically 
administered glucocorticoids. 
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0.2  Zusammenfassung 
 
Ovarialkarzinome verursachen allein in Deutschland jährlich ca. 6.000 Todesfälle. Da bei 
Ovarialkarzinomen, die eine Resistenz gegen eine platinbasierte Chemotherapie mit cis-Platin 
und gegen Paclitaxel entwickelt haben, nur eine palliative Behandlung möglich ist, gibt 
esbesteht ein dringenden dringender Bedarf an der Entwicklung von neuen Therapieansätzen. 
Das Überleben der Patientinnen ist sehr stark von immunologischen Parametern beeinflusst, 
und somit erscheinensodass immuntherapeutische Strategien als ein vielversprechender 
Ansatzerscheinen. Das Ziel der Forschung in unserer Gruppe ist daher, dem „Tumor-Immun-
Escape“ durch eine Verhinderung von immunosuppressiven Mechanismen in im der 
Tumormikromilieu-Mikroumgebung entgegenzuwirken. 
 
In diesem Zusammenhang haben wir gefundenentdeckt, dass Tumor-infiltrierende 
Suppressorzellen der myeloiden Ursprungsschen Reihe (MDSC) oder Tumor-assoziierte 
Makrophagen (TAM), die in Ovarialkarzinomen reichlich vorhanden sind, das Enzym 11β-
Hydroxysteroid-Dehydrogenase 1 (11β-HSD1) in großer Menge exprimieren. Diese Oxido-
Reduktase ist essentiell bei derfür die Umwandlung von biologisch inaktiven Cortison in 
biologisch aktives Cortisol. In Übereinstimmung damit, werden hohe endogene Cortisol 
Spiegel in Seren, Azites und Tumorsekreten von Ovarialkarzinom-Patientinnen gemessen. 
Unter Berücksichtigung der starken anti-inflammatorischen und immunsuppressiven 
Eigenschaften von Cortisol, erscheint es sehr wahrscheinlich, dass ein hoher endogener 
Cortisol-Spiegel zum „Immune-Escape“ von Ovarialkarzinomzellen beiträgt. Unsere 
Vermutung ist Wir stellten daher die Hypothese auf, dass die lokale Aktivierung von 
endogenen Glucocorticoiden zu einer Unterdrückung der nützlichen Immunantwort in der 
Tumor-Mikroumgebung führt und eine erfolgreiche Immuntherapie verhindert. 
 
Um die in vivo Relevanz dieses postulierten „Immune-Escape“ Mechanismuses zu 
untersuchen, wurden bestrahlte PTEN
loxP/loxP 
loxP-Stop-loxP-kras
G12D
 Mäuse mit 
Hämatopoetischen hämatopoietischen Stammzellen entweder aus Glucocoprticoid-Rezeptor 
(GR) exprimierenden Mäusen (GR
loxP/loxP
) oder aus Mäusen mit einem T-Zell spezifischen 
Glucocoprticoid-Rezeptor knock-out (lck-Cre GR
loxP/loxP
) rekonstituiert. In diesen Mäusen 
führte die Kombination von konditionellem PTEN knock-out mit einer latenten Expression 
von oncogenen onkogenen Kras zur Tumorentwicklung sobald ein für Cre-Rekombinase 
codierendes Adenovirus in die Ovarien-ovarielle Bursa injiziert wurdewird. Mit Hilfe von 
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diesesm Modells wurde gezeigt, dass Mäuse, die mit GC-unempfindlichen T-Zellen 
rekonstituiert worden waren eine bessere intratumorale T-Zell Infiltration zeigten im 
Vergleich zu Kontroll-Mäusen, die über einen adaptiven Transfer funktionell unveränderte 
GR
loxP/loxP 
Zellen erhalten hatten. Tumor-infiltrierende T-Zellen haben aber in der Mehrzahl 
einen hauptsächlich angenommen Foxp3+ (regulatorischen) Phänotyp angenommen, sodass 
und das Überleben dieser Zellen war sogar verkürzt in Mäusen mit Cortisol-unempfindlichen 
T-Zellen sogar eine verkürzte Überlebenszeit aufwiesen. Somit scheint endogenes Cortisol die 
Infiltration von Immunzellen beim Ovarialkarzinom zu inhibieren, aber eine produktive 
antitumorale Immunantwort könnte scheint trotzdem verhindert werden durch andere 
Faktoren aus im Tumormikromilieu verhindert zu werden.der Tumor-Mikroumgebung. 
 
Somit bieten unsere Daten keine ausreichend starke Begründung, für eineum das Konzept der 
Antagonisierung endogener,der durch Glucocorticoide ausgelösten ausgelöster Signale in 
Ovarialkarzinom-Patientinnen weiter zu verfolgen. Des Weiteren werden Glucocorticoide oft 
Krebspatienten verabreicht, um Entzündungen und Schwellungen zu reduzieren sowie 
Chemotherapie. bedingte Nebeneffekte wie Übelkeit oder Überempfindlichkeitsreaktionen, 
die mit einer Paclitaxel-Therapy einhergehen,  zu verhindern. Daher wurde der Frage 
nachgegangen, ob spezifische Signalwege im angeborenem Immunsystem, insbesondere in 
NK-Zellen, auch in Anwesenheit von GC noch aktiviert werden können. Eine Untersuchung 
der verschiedenen NK-Zellen aktivierenden Rezeptoren (NKp30, NKp44, NKp46, DNAM-1 
und NKG2D) wurde durchgeführt. Dabei wurde eine Herunterregulation von NKp30, NKp44 
und NKG2D sowie eine Induktion von NKp46 durch Cortisol festgestellt. 
 
Von besonderem Interesse ist, dass NKp46 der einzige bekannte Rezeptor ist, der nur von 
NK-Zellen exprimiert wird. Seine Aktivierung bewirkt eine Cytokinfreisetzung 
Zytokinfreisetzung und eine Aktivierung Induktion der zytotoxischen AktivitätNK Zell-
Antwort. Eine Stimulation der NK-Zellen über NKp46 könnte zur immun-vermittelten 
Tumorzerstörung durch Auslösen der Tumorzell-Lyse und durch eine Veränderung des 
Cytokinexpressionsmusters Zytokinexpressionsmusters in im Tumormikromilieu der Tumor-
Mikroumgebung beitragen. Somit würden verbesserte Bedingungen für die Rekrutierung von 
antigen-spezifischen Immunzellen generiert. Unsere Beobachtung, dass selbst Cortisol 
behandelte NK-Zellen immer noch über NKp46 und CD2 aktiviert werden können, könnten 
nützlich zur Entwicklung von Immuntherapien sein, die in Gegenwart von endogenen oder 
therapeutisch verabreichten Glucocorticoide angewendet werden sollen. 
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1 Introduction 
1.1 Ovarian cancer 
1.1.1 Epidemiology, diagnosis, classification, prognosis, therapy 
 
Ovarian carcinoma is one of the leading causes of death from gynecological malignancies in 
the western world (Fehrmann et al., 2007). Internationally; ovarian cancer is the sixth most 
common cancer among women (Riman et al., 1998). 
 
Ovarian cancer is the 2nd most common violent affection of the female sexual organs, and it 
is mostly diagnosed in women aged >40 years. Due to the lack of cancer screening tests, 
ovarian carcinomas are frequently diagnosed at late stages. In Germany 9000 (Europe 66,000) 
new ovarian cancer cases and 5,500 (Europe 40,000) deaths were registered in 2008 
(http://www.oncgnostics.com). 
 
The causes of ovarian cancer are poorly understood. Ovarian cancer is thought to be 
consequence of result from an accumulation of genetic alterations (Aunoble B et al., 2000; 
Fehrmann et al., 2007). Over 90% of ovarian cancers occur sporadically. Ovulation appears to 
increase the danger as does family history, increasing age, infertility, and usage of ovulatory 
drugs. Pregnancy and the use of oral contraceptives, as well as possibly breast-feeding, lower 
the risk. Furthermore, tubal ligation or hysterectomy with ovarian preservation also lowers the 
risk (Herbst, 1994). The median age of patients with ovarian cancer is 60 years, and the 
average life span risk for women is about 1 in 70. A strong family history of ovarian or breast 
cancer is the major risk factor, while genetic predisposition is present in about 5 % of affected 
women (Cannistra, 2004). 
 
Epithelial ovarian tumours, germ cell tumours and sex cord/stromal tumours are the main 
types of ovarian tumours. Epithelial ovarian tumours which constitute 80–90% of ovarian 
malignancies resulting are (according to recent findings) mostly derived from the surface 
epithelium of the fimbriated end of the fallopian tube (Dietl & Wischhusen, 2011) and 
constitute 80–90% of ovarian malignancies. Approximately, 15% of the epithelial tumours are 
borderline malignant while the rest are invasive cancers. There are several histopathological 
subgroups of epithelial ovarian cancers (EOC) (Riman et al., 1998). It has been reported that 
the EOC were categorized as follows: serous adenocarcinoma (43%), mucinous 
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adenocarcinoma (15%), endometroid adenocarcinoma (22%), clear cell adenocarcinoma (5%) 
and mixed or undifferentiated tumours (14%) (Booth et al., 1989; Riman et al., 1998). 
 
The early discovery of ovarian cancer considerably decreases the mortality rate of ovarian 
cancer patients. For early detection of ovarian cancer, six markers (leptin, prolactin, 
osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) are 
utilized to distinguish healthy versus cancer patients. The use of six markers showed great 
diagnostic improvement (sensitivity 84%-98% at specificity 95%) over the use of only CA-
125 alone (sensitivity 72% at specificity 95%) (Visintin et al., 2008). 
 
The majority of cases are diagnosed at an advanced stage and the prognosis is poor, with 5-
year survival rates less than 40%. Yearly, more than 100.000 women are estimated to die 
from the ovarian cancer (Parkin et al., 1993; Riman et al., 1998). Some classical clinic-
pathological factors, such as age, stage, residual tumour after first laparotomy, differentiation 
grade, histiotype, and response to chemotherapy are vital prognostic markers for ovarian 
cancer (du Bois A et al., 2005; Fehrmann et al., 2007). Also, microarray technology at the 
present permits analysis of expression levels of thousands of genes and is broadly used to 
identify prognostic gene-expression profiles for all sorts of cancer (Fehrmann et al., 2007). 
 
Generally, the first treatment for ovarian cancer is surgery which will consist of removal of 
the uterus, tubes and ovaries as well as any large nodules of cancer 
(http://www.gyncancer.com/ovarian-cancer.html). Furthermore, due to a possible contribution 
of pelvic and paraaortic node in ovarian carcinoma metastasis a bilateral lymphadenectomy is 
an important step in the surgical treatment of EOC and has a diagnostic, prognostic and 
therapeutic value (Morice et al., 2003). 
 
Most patients will be left with residual disease and will therefore require postoperative 
chemotherapy after surgical removal of ovarian cancer (Berkenblit and Cannistra, 2005). 
Platinum-based chemotherapy (cisplatin or carboplatin) is a practical primary step for the 
chemotherapy (Harries and Kaye, 2001; Berkenblit and Cannistra, 2005). Also, it has been 
reported that addition of taxanes to platinum-containing regimens brings a significant benefit 
and the standard of care has become the combination of carboplatin and paclitaxel (Harries 
and Kaye, 2001; Berkenblit and Cannistra, 2005). Still, the majority of patients with late stage 
ovarian cancer will relapse and will be candidates for further chemotherapy, which can 
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palliate symptoms and improve survival rate even in recurrent disease (Harries and Kaye, 
2001). Radiotherapy, in contrast, cannot be applied since ovarian carcinomas grow close to 
the extremely radio-sensitive gut that would be too severely affected by irradiation treatment. 
 
1.1.2 Spontaneous mouse model for ovarian cancer (Dinulescu et al., 2006) 
 
A Tyles Jacks and colleagues developed a spontaneous mouse model to recapitulate 
endometrioid ovarian cancer which is characterized by an inactivation of the tumor suppressor 
PTEN and a hyperactivation of kras used to investigate the functional immunomodulatory 
role of endogenous glucocorticoids in ovarian cancer. For this model, an adenovirally 
encoded Cre-recombinase (AdCre) was is injected directly into the ovarian bursa of 129 
S4/SvJae-C57BL/6JloxP-Stop-loxP-K-ras
G12D/+
Pten
loxP/loxP 
mice to induce the deletion of the 
PTEN tumour suppressor gene and the activation of the latent oncogenic K-ras
G12D
 (Dinulescu 
et al., 2006). Due to the deletion of PTEN and the activation of K-ras, the mice developed 
ovarian cancer of the endometrioid subtype which becomes immunohistochemically 
detectable visible within 6-7 weeks. Later, the mice also developed peritoneal metastases as 
evidenced by the formation of ascites in the abdominal cavity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1): Spontaneous mouse model for ovarian cancer. Injection   of   adenoviral   Cre-
recombinase   into   the   ovarian bursa induces the deletion of the PTEN tumour suppressor 
gene and the activation of the latent oncogenic K-ras.  Mice thus developed an endometrioid 
ovarian carcinoma within 6-7 weeks (B). No cancer developed in contralateral non-treated 
ovaries (A). Experiment performed and photographed by Dr. Sebastian Häusler. 
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1.2 Adrenal Glucocorticoids 
 
Glucocorticoids (GCs) (Cortisol and Corticosterone) are a group of steroid hormones that 
bind to the glucocorticoid receptor (GR), which is present in almost every vertebrate animal 
cell. The name GC (glucose + cortex + steroid) derived from their function in the regulation 
of the metabolism of glucose and from, their synthesis in the adrenal cortex. 
 
Hydrocortisone (Cortisol) is the most vital human GC. It is necessary required to regulate or 
support a variety of vital cardiovascular, metabolic, immunological, and homeostatic 
functions. Additional to that, various synthetic GCs are obtainable such as dexamethasone; 
these are used either as alternative therapy in GC deficiency or to inhibit the immune system 
in autoimmune diseases and to stop ameliorate chemotherapy-related side effects. 
 
By their mode of action, GCs bind to the cytosolic GR which then translocates to the nucleus 
where it binds to Glucocorticoid response elements (GRE) thereby leading to an up-regulation 
of anti-inflammatory protein expression (transactivation). In the cytosol, GCs can further 
repress the expression of pro-inflammatory proteins by preventing the translocation of other 
transcription factors from the cytosol into the nucleus (transrepression) (Rhen and Cidlowski, 
2005). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure (2): Mode of action of GCs (http://www.epgonline.org). 
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1.2.1 Origin of Adrenal Steroids 
 
Adrenal steroids are a group of steroid hormones secreted and synthesized by the adrenal 
cortex. Adrenal steroids can be categorized as GCs (cortisol and corticosterone), 
mineralocorticoids (aldosterone), androgens dehydroepiandrosterone (DHEA) and 
androstenedione. All steroid hormones are derivatives of Cholesterol which require numerous 
enzymatic steps during the synthesis of adrenal steroids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (3): Pathways of steroid biosynthesis in the adrenal cortex (White, 2009). 
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1.2.1.1 Systemic control of cortisol secretion regulated by the hypothalamic-pituitary-
adrenal axis 
 
Systemically, secretion of adrenal GC is coordinated by the hypothalamus-pituitary-adrenal 
axis. Neuroendocrine stimuli delivered to hypothalamus which govern GCs release are stress 
(Tasker et al., 2006) and pro-inflammatory cytokines (IL-1, IL-6, and TNF-) (Turnbull and 
Rivier, 1999). In addition, the circadian rhythm generator (Abe et al. 1979; Vrang et al. 1995) 
and a negative feedback loop (Tasker et al., 2006) influence the availability of cortisol. About 
75% of the cortisol in circulation is bound to a plasma protein called the corticosteroid 
binding globulin (CBG), while the rest is bound to serum albumin. Normally, cortisol in 
circulation is inactive, and only becomes biologically active when it becomes unbound from 
transcortin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4): Systemic control of cortisol secretion regulated by the hypothalamic-
pituitary-adrenal axis (Open access image from wikipedia website). 
 
Hypothalamus stimuli: Stress, pro-inflammatory cytokines (IL-1, IL-6, and TNF-
), circadian rhythm generator, feedback loop 
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1.2.2 Local control and metabolism of GCs 
The local regulation of GCs in the tissues is controlled by 11beta-Hydroxysteroid 
dehydrogenases (11β-HSD). The two iso-enzymes 11β-HSD1 and 11β-HSD2 catalyse the 
interconversion of hormonally active cortisol (F) and inactive cortisone (E). Both isoenzymes 
are localized in endoplasmic reticulum. The type 1 and type 2 11β-HSD isozymes share only 
14% homology and are separate gene products with different physiological roles, different 
regulation, and different tissue allocation (Stewart and Krozowski, 1999; Vogt et al., 2002; 
Michael et al., 2003; Walker and Stewart, 2003). In vivo, 11β-HSD1 acts mostly as an 
oxidoreductase using NADP (H) as cofactor to generate cortisol. In vitro, however, its activity 
is bidirectional, acting as dehydrogenase (cortisol to cortisone) and reductase (cortisone to 
cortisol). 11-HSD2, in contrast, acts exclusively unidirectional as NAD-dependent 
dehydrogenase, inactivating cortisol to cortisone (Walker and Stewart, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (5): Local control and metabolism of GCs via 11β-HSD isozymes (Draper and 
Stewart, 2005). 
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Table (1): Comparison between 11β-HSD1 and 11β-HSD2 isozymes (Draper and Stewart, 
2005). 
 11-HSD1 11-HSD2 
Chromosomal 
location 
1q32·2 16q22 
Size Gene: 30 kb, 6 exons 
Protein: 292 aa, 34 kDa 
6.2 kb, 5 exons 
405 aa, 44 kDa 
Enzyme family Short chain 
dehydrogenase/reductase 
superfamily 
Short chain  
dehydrogenase  
superfamily 
Tissue expression Liver, lung, gonads, 
pituitary, brain, adipose 
Kidney, colon, salivary glands 
placenta 
Enzyme kinetics In vitro bidirectional 
In vivo mainly reductase 
Cofactor NADP(H) 
Only dehydrogenase 
Cofactor NAD 
Function Supplies cortisol to GR Protects MR from cortisol 
 
1.2.2.1 Regulation of expression and activity of 11β-HSD1 
 
11β-HSD1 expression and activity are regulated by different factors such as pro-inflammatory 
and anti-inflammatory cytokines, IL-1α, (Yong et al., 2002; Chapman et al., 2006), IL-1β 
(Escher et al., 1997; Cai et al., 2001; Tomlinson et al., 2001; Li et al., 2006; Chapman et al., 
2006), TNF-α (Escher et al., 1997; Thieringer et al., 2001; Cai et al., 2001; Tomlinson et al., 
2001; Chapman et al., 2006), IL-6 (Tomlinson et al., 2001; Friedberg et al., 2003), IL-4 and 
IL-13 (Thieringer et al., 2001; Hardy et al., 2006). Moreover, combined treatment with GCs 
(Cortisol or Dexamethasone) increases the expression of 11β-HSD1 (Tomlinson et al., 2002, 
Sun and Myatt, 2003; Li et al., 2006) and in combination with pro-inflammatory cytokines 
(TNF-α/IL-1β) synergistically increases expression and activity of 11β-HSD1 (Sun and 
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Myatt, 2003; Yang et al., 2009; Kaur et al., 2010; Ahasan et al., 2012). On the other hand, 
TNF-α/IL-1β down-regulated regulates the 11β-HSD2 expression (Cai et al., 2001; Cooper et 
al., 2001). 
 
1.2.2.2 11β-HSD1and ovarian surface epithelium  
 
Ovulation is a natural inflammatory event which includes haemodynamic, vascular, and 
biochemical changes leading to proteolytic breakdown of the follicle wall and release of an 
oocyte for fertilization (Espey, 1980; Hillier and Tetsuka 1998; Hillier, 2007). Many pieces of 
evidence indicate that the ovarian single-layered epithelium participates in repair of the 
ovarian surface after the „wounding‟ caused by ovulation (Michael et al., 2003) though an 
involvement of epithelial cells from the fallopian tube has also been described (Dietl et al., 
2011).Young et al showed that ovarian surface epithelial (OSE) cells express 11β-HSD1 and 
this expression can be up-regulated by pro-inflammatory cytokines such as IL-1 (Yong et al., 
2002; Rae et al.  2004), this leads to a local anti-inflammatory environment since enhanced 
expression and thereby enhanced oxo-reductive activity of 11β-HSD1 increases the local 
availability of cortisol.  This mechanism is thought to occur as a reaction to the ovulation-
inducing LH surge (Yong et al., 2002) and is likely to contribute to the local resolution of 
inflammation during ovulation. In a pathological context, the pro- and anti-inflammatory 
processes involved in ovulation as injury-repair process may contribute to development of 
ovarian cancer, especially since many processes that are required for wound healing can also 
contribute to tumour growth (Schäfer and Werner, 2008). On the other hand, epidemiological 
data show that ovarian epithelial inflammation may play a role in ovarian carcinogenesis 
(Ness and Cottreau, 1999; Ness et al., 2000; Yong et al., 2002; Fleming, et al. 2006). 
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Figure (6): Role of 11β-HSD1 in the resolution of inflammation at the ovarian surface 
during ovulation. The ovulation-inducing LH surge induces an acute inflammatory response 
through increasing the local production of inflammatory cytokines (IL-1) and prostaglandins 
(PG). LH-induced IL-1 consecutively up-regulates the expression of 11β-HSD1 in granulosa 
cells and OSE cells, helping to increase the metabolism of inactive cortisone (E) into active 
anti-inflammatory cortisol (F) (Yong et al., 2002; Kenneth Scott Fegan, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (7): Intracrine amplification of anti-inflammatory GC action by 11β-HSD1. (1) 
Pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor (TNF-
) increase the expression of inflammatory mediators, such as cyclo-oxygenase-2 (COX-2) 
and matrix metalloproteinase-9 (MMP-9). The inflammatory response includes an associated 
increase in 11β-HSD1 (and/or reduced 11β-HSD2) expression on mRNA level and enhances 
11-oxoreductase enzymic activity. (2) Cytokine-induced inflammatory mediators bring about 
haemodynamic, vascular and biochemical changes associated with inflammation. (3) Active 
cortisol (F) formation from inactive cortisone (E) is locally increased due to cytokine-
enhanced 11-oxoreductase activity of 11β-HSD1. Increased binding of cortisol (F) to the 
glucocorticoid receptor (GR) activates GR-mediated post-receptor anti-inflammatory 
signalling leading to resolution of inflammation (Tetsuka et al. 1999; Yong et al. 2002; Rae et 
al. 2004; Hillier, 2007). 
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1.2.2.3 11β-HSD1 expression in immune cells 
 
11β-HSD1 has a role in the regulation of energy metabolism and the immune system by 
locally activating GCs (Nashev et al., 2007). Thieringer et al. showed that 11β-HSD1 is not 
constitutively expressed in human monocytes, but rather induced in human monocytes upon 
differentiation to macrophages. Further induction is possible in response to the cytokines IL-4 
and IL-13 (Thieringer et al., 2001). On the other hand, human monocyte-derived DCs are able 
to activate cortisone to cortisol as a consequence of up-regulated expression of the enzyme 
11β-HSD1 (Freeman et al., 2005). In mice, a single injection of thioglycolate into the 
peritoneum was sufficient to elicit an induction of 11β-HSD1 activity in macrophages, which 
then increased intracellular levels of active GCs, thereby promoting macrophage phagocytosis 
of leukocytes undergoing apoptosis (Gilmour et al., 2006). Moreover, Zhang et al 
demonstrated that 11β-HSD1 transcripts, protein, and enzyme activities are found in murine 
CD4
+
, CD8
+
, and B220
+
 lymphocytes, as well as CD11c
+
  DCs (Zhang et al., 2005). 
 
1.2.3 GCs effects on the immune cells 
 
Regulation of GCs is essential for the maintenance of immune homeostasis.  GCs can be 
employed in situations to avoid excessive immunosuppression, death from overwhelming 
infection, or death from cytokine storm induced shock (Sternberg, 2006). GCs can affect 
immune cells directly and indirectly via increasing amounts of anti-inflammatory cytokines 
and decreasing levels of pro-inflammatory cytokines. Moreover, GC can induce apoptosis in 
all immune cells and inhibit the immune response (Sternberg, 2006). 
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Figure (8): GCs effects on the immune cells. GCs act on immune cells both directly and 
indirectly to suppress the induction of pro-inflammatory responses. They inhibit the 
production of pro-inflammatory cytokines, such as interleukin-1beta (IL-1) and tumour-
necrosis factor-alpha (TNF-), while promoting the production of anti-inflammatory 
cytokines, such as IL-10, by macrophages and DCs. They also promote apoptosis of 
macrophages, DCs and T cells, leading to inhibition of immune responses (Sternberg, 2006). 
 
1.2.4 GCs and Ovarian Cancer 
 
Several studies have described high levels of cortisol in saliva, blood and ascites from ovarian 
cancer patients. In these patients, a dysregulation of diurnal cortisol levels leading to greater 
functional disability, fatigue and depression was assumed and implications for disease 
progression could not be excluded (Touitou et al., 1996; Lutgendorf et al., 2008; Weinrib et 
al., 2010).  
25 
 
Synthetic GCs such as dexamethasone are administered to patients with ovarian cancer as co-
treatment with chemotherapy to prevent chemotherapy-related toxic side effects. GCs have 
potent anti-emetic effects, protect normal tissue and can prevent hypersensitivity reactions 
associated with paclitaxel therapy (Runnebaum and Brüning, 2005; Zhang et al., 2006; Sui et 
al., 2006; Melhem et al., 2009; Chen et al., 2010). 
 
There is some evidence that stress can affect cancer progression (Sood et al., 2006; Thaker et 
al., 2006). Furthermore, stress hormones have been reported to increase the tissue expression 
of matrix metalloproteinases (MMP), key proteins involved in tumour cell penetration of the 
extracellular matrix and in tumour progression (Sood et al., 2006). Via these mediators, stress 
hormones are thought to promote the invasive and metastatic potential of ovarian carcinoma 
cells. Moreover, tumours in stressed animals showed significantly increased vascularization 
and angiogenesis due to up-regulation of expression of VEGF, MMP2 and MMP9, which 
resulted in enhanced tumour growth (Thaker et al., 2006). 
 
As already mentioned, GCs are frequently used as a co-treatment in cytotoxic cancer 
chemotherapy with drugs like cisplatin and paclitaxel, in order to prevent the related toxic 
side effects e.g. to stop nausea and to guard normal tissue. However, several studies have 
reported that this use of GCs could render cancer cells more resistant to apoptosis induced via 
cytotoxic chemotherapy since GCs may also up-regulate expression of survival genes like the 
caspase inhibitor cIAP2. Thus, GCs may reduce the effectiveness of anti-tumour 
chemotherapy by promoting resistance and anti-apoptotic properties in epithelial ovarian 
cancer cells (Runnebaum and Brüning, 2005; Sui et al., 2006; Zhang et al., 2006; Chen et al., 
2010). 
 
1.3 Transforming growth factor-beta in Ovarian Cancer 
 
Transforming growth factor-beta proteins (TGF-β) are a family of polypeptide cytokines 
which regulate cell growth, tissue remodeling, development, tissue recycling, repair and 
immune suppression (Massagué, 1996; Bartlett et al., 1997). The immune suppressive and 
tissue remodeling activities of these growth factors propose a role in tumour metastasis, while 
angiogenic effects may contribute to tumour growth (Bartlett et al., 1997). 
 
26 
 
Three forms of TGF- have been identified, namely TGF-1, TGF-2 and TGF-3, in homo-
dimeric chains of between 111 and 113 amino acids, with molecular weights of 25 kDa. These 
growth factors act together with cell surface serine-threonine kinase linked receptors which 
mediate their tissue regulatory effects (Massagué et al., 1992; Wrana et al., 1994; Bartlett et 
al., 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (9): Targets of TGF- and its actions in mature tissues. TGF-helps to maintain 
tissue homeostasis by controlling the proliferation of various cell types including epithelial, 
endothelial, stromal fibroblasts and immune cells as well as by influencing the interaction of 
these cells with the tissue microenvironment (Siegel and Massagué, 2003). 
 
TGF- is released from every leukocyte lineage, including lymphocytes, macrophages, and 
dendritic cells (DCs) (Letterio and Roberts, 1998). Also, it has been mentioned that TGF- is 
secreted by malignant cells, mesenchymal cells, regulatory T cells (Treg), macrophages, 
neutrophils, NK T cells, monocytes, DCs, mast cells and platelets (Teicher, 2007). 
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TGF- is a key player in malignant disease through its actions on host tissues and cells. 
Malignant cells mostly secrete large amounts of TGF- that act on non-transformed cells 
present in the tumour mass as well as on distal cells in the host to suppress anti-tumour 
immune responses inducing an environment of immune tolerance, augmenting angiogenesis, 
invasion and metastasis, and increasing tumour extracellular matrix deposition (Teicher, 
2007). 
 
Local and systemic secretion of TGF- as an immunosuppressive cytokines may have an 
important role in the impaired anti-tumour immune response commonly observed in advanced 
ovarian cancer. However, the observation that plasma levels of TGF- are significantly higher 
than those detected in ascitic fluid, increases the possibility that cells other than tumour cells 
are in charge of release TGF- release into the bloodstream of these patients (Santin et al., 
2001). 
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Figure (10): Role of TGF-β in Cancer. In  normal  and  premalignant cells,  TGF-β  
enforces  homeostasis  and suppresses tumour progression directly through cell-autonomous 
tumour-suppressive effects  (cytostasis, differentiation, apoptosis) or indirectly through effects 
on the stroma (suppression of inflammation and stroma-derived mitogens). However, when 
cancer cells lose TGF-β tumour-suppressive responses, they can use TGF-β to their advantage 
to initiate immune evasion, growth factor production, differentiation into an invasive 
phenotype, and metastatic dissemination or to establish and expand metastatic colonies 
(Massagué, 2008). 
 
Expression of TGF-β isoforms has been described in ovarian tumours (Henriksen et al.1995; 
Nash et al., 1999; Abendstein et al., 2000; Teicher, 2007) and high levels of TGF-β were also 
detected in ovarian cancer-associated ascites (Hirte & Clark 1991; Zeimet et al., 1998; Nash 
et al., 1999; Abendstein et al., 2000; Santin et al., 2001). In primary ovarian cancer and 
ascites, however, the respective distribution of the individual TGF- isoforms was rather 
variable ranging from 46% (for TGF-β1) to 66% (for TGF-β2 and TGF-β3) of 74 malignant 
tumours (Bartlett et al., 1997). Still, irrespective of the isoform there is ample evidence that 
high levels of released TGF-β lead to disease progression (Merogi et al., 1996; Nakanishi et 
al., 1997; Abendstein et al., 2000).  
 
1.4 GCs and TGF- 
 
GCs and TGF- mutually contribute to limiting and/or terminating inflammatory processes 
and are both involved in the regulation of cell growth, development and differentiation. 
Moreover, GCs and TGF- do not act separately of each other but modulate each other‟s 
activities (Periyasamy and Sánchez, 2002; Peltier et al., 2003). GCs up-regulate the 
expression of TGF- receptor type II and improve the responsiveness and sensitivity of cells 
to TGF-1 signaling (Li et al., 2006; Chen et al., 2010). Furthermore, GCs up-regulate TGF- 
mRNA expression in human T lymphocytes (AyanlarBatuman et al., 1991; Peltier et al., 
2003) and macrophages (Almawi and Irani-Hakime, 1998; Peltier et al., 2003). Moreover, 
dexamethasone also promotes the activation of latent TGF-by inducing the secretion of 
lysosomal proteases, responsible for the cleavage of the latency-associated peptide (Oursler et 
al., 1993; Peltier et al., 2003). On the other hand, TGF-1 alone not only increased cell 
adhesion and cell survival of HO-8910 cells in the presence of cisplatin, but also showed 
synergistic pro-adhesion and pro-survival effects with dexamethasone. Based on this 
observation, it was hypothesized that the ability of TGF- signaling to increase adhesion of 
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human ovarian cancer cells to their extracellular matrix could significantly contribute to the 
previously described induction of chemo-resistance by GCs (Chen et al., 2010). It was further 
described that a TGF-1-induced, Smad 2, 3- and AP-1-mediated process enhances 
glucocorticoid binding in inflammatory cells and thus improves responsiveness and sensitivity 
of these cells to glucocorticoids. Accordingly, the TGF- pathway may represent a new target 
for intervention to increase glucocorticoid responsiveness (Peltier et al., 2003). Likewise, 
TGF-potentiates the inhibitory role of dexamethasone on the growth of monocytic leukemia 
cells (Kanatani et al., 1996; Peltier et al., 2003). 
 
1.5 Natural killer cells 
 
Natural killer cells (NK cells) are large granular lymphocytes first described in 1975 as cells 
able to kill tumour cells in vitro.  NK cells which constitute about 5-15% of the human 
peripheral blood lymphocytes from a healthy donor, are a vital part of the innate immune 
system and play a major role in the rapid immune responses against tumour cells and virus 
infected cells (Kiessling et al., 1975; Herberman et al., 1975; Riccardi et al., 1980; Ljunggren 
and Karre, 1985; Natuk and Welsh 1987; Salazar-Mather et al., 1998; Biron et al., 1999; 
Janeway, 5th Edition, 2005; Lodoen and Lanier; 2006). 
 
Natural killer cells distinguish and lyse tumour cells and virus infected cells without previous 
priming to antigens (Herberman et al., 1975; Moretta et al, 2000; Terunuma et al., 2008), even 
though recent reports suggest that antigen-experienced NK cells can show superior efficacy 
(Sun et al., 2009; Paust and von Andrian, 2011). In vivo experiments have shown that NK 
cells can mediate resistance to tumour growth in mice and rejection of bone marrow 
transplants (Kiessling et al., 1975, 1977; Riccardi et al., 1980; Herberman and Ortaldo, 1981; 
Hanna, 1982). Moreover, NK cells play an important role against tumour promotion, growth 
and metastasis in rodents and humans (Smyth et al., 2002). Detection of human NK cells is 
usually based on identification of the lymphocytes that are negative for CD3
- 
and positive for 
CD16
+
 and CD56
+
 (Terunuma et al., 2008). The most specific NK cell receptor, however, 
appears to be NKp46 (Walzer et al., 2007). 
 
Upon stimulation of NK cells they release a number of cytokines, such as IFN-γ, TNF-, 
granulocyte–macrophage colony-stimulating factor (GM-CSF), IL-5, IL-10 and IL-13 (Biron 
et al., 1999; Cooper et al., 2001; Moretta et al, 2001; Loza et al., 2002; Smyth et al., 2002; 
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Martin-Fontecha et al., 2004; Caligiuri, 2008; Terunuma et al., 2008). Moreover, cytokines 
and chemokines in the inflamed environment support the differentiation, proliferation and 
recruitment of NK cells (Smyth et al., 2002). 
 
NK cells can establish contact with a target cells via CD16 which is a low-affinity activating 
Fc receptor that allows NK cells to bind to IgG-coated target cells, thus, inducing antibody-
dependent cellular cytotoxicity (ADCC) as well as secretion of IFN-, TNF-, and T- cells 
chemotactic recruiting cytokines (Trinchieri and Valiante, 1993; Lanier, 2005; Roda et al., 
2006; Terunuma et al., 2008). However, NK cells can not only recognize “antibody-tagged” 
cells but also cells that express ligands for natural cytotoxicity receptors (explained in more 
detail below). 
 
In spite of being part of innate immunity, NK cells are more closely related to T cells than to 
other leukocytes of the immune system. In fact, NK cells possess similar cytotoxic effector 
functions of cytotoxic T lymphocytes (CTL) and their cytokine-secreting properties resemble 
TH1 helper T cells (Lanier, 2005),  Still, NK cells differ substantially from T cells which only 
recognize their cognate peptide antigen when presented on the right major histocompatibility 
complex (MHC). While this enables the exquisite antigen specificity of T cells, it comes at the 
price that no effective number of defenders against all possible antigens can be maintained in 
“standby mode”. Thus, T cells require previous priming to antigens, gene rearrangement 
during development and clonal expansion before they can mount an effective immune 
response. NK cells, in contrast, constitute a first line of defense. Moreover, a successful NK 
cells response is accompanied by release of IFN- which then leads to activation of the 
adaptive immunity and initiates a Th1 immune response (Cooper et al., 2001; Martin-
Fontecha et al., 2004; Raulet, 2004). Thereby, NK cells play an important role as link between 
the innate immunity and adaptive immunity to get rid of virus-infected or tumour cells by 
acting as mediator and effector cells in the immune system (Smyth et al., 2002). Furthermore, 
NK cells are considered to play a role in development of adaptive immunity through cross-
talk with antigen-presenting DCs (Smyth et al., 2002). 
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Figure (11): NK cells and anti-tumour immune responses (Smyth et al., 2002). 
 
Natural killer cells are thought to play a major role in anti-tumour immunity and in networks 
of immune cells that respond to tumours (Fernandez et al., 1999; Smyth et al., 2002; Zamai et 
al., 2007). NK cells can not only lyse tumour cells directly (in response to stress-associate or 
antibody-mediated or other signals). They also influence the development of adaptive T- and 
B-cell immune responses which are instrumental for specific immunity and immunological 
memory to tumours and pathogens. NK cell-derived cytokines, such as interferon IFN-, 
activate CTL and helper T-cell (CD4
+
) responses, leading to T cell proliferation and further 
cytokine production (Smyth et al., 2002). 
 
NK cells can recognize tumour cells via different ligand-receptor interactions which result in 
the release of cytokines and in the formation of an immunological synapse with a target cell 
(Lanier, 2005). NK cells are further capable of lysing tumour cells via different effector 
mechanisms, including the expression of death ligands to activate the death-receptor pathway, 
the IFN-γ-mediated pathway and the exocytosis of cytolytic granules containing perforin and 
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granzymes (Smyth et al., 2002). The inner surface of these cytotoxic granules is coated with 
the lysosomal–associated membrane protein-1 (LAMP-1 or CD107a) which translocates to 
the surface of NK cells upon degranulation. The presence of LAMP-1 at the cell surface is 
thus considered as marker for activated NK cells (Peters et al., 1991; Fukuda, 1991; Alter et 
al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure (12): Role of NK cells in the elimination of tumour cells. NK cells can use the 
perforin/ granzyme granules exocytosis pathway (a), the death-receptor-ligand pathway (b) or 
the IFN-, nitric oxide pathway (c) to kill tumour cells (Smyth et al., 2002). 
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NK cells express a number of inhibitory receptors that recognize major histocompatibility 
complex (MHC) class I molecules which are expressed on normal cells. NK cells are able to 
distinguish between normal major histocompatibility complex class I positive (MHC class I
+
) 
cells and cells that either lack or down-regulate their expression of MHC class I molecules as 
an outcome of tumour transformation or viral infection. The concept that NK cells lyse target 
cells which lack expression of one or more MHC class I alleles or that express insufficient 
amounts of class I molecules was called the “missing self hypothesis” by Ljunggren and 
Karre. Current models propose that NK cell functions are controlled by the balance of 
inhibitory and activating signals which they receive through their various classes of receptors 
(Ljunggren and Karre, 1985; Karre et al., 1986; Ljunggren and Karre, 1990; Moretta et al., 
1996; Moretta et al., 2000; Moretta et al., 2001; Smyth et al., 2002). The link between NK cell 
triggering and inhibition is further emphasized by the fact that an efficient negative regulation 
of NK cell function requires the co-engagement of both activating and inhibitory receptors 
(Bléry et al., 1997; Moretta et al., 2000). 
 
Interactions between activating receptors and their ligands on target cells enable NK to lyse a 
given target cell. Many of these activating ligands can be up-regulated upon infection or 
transformation of the cells or by other stress stimuli acting on cells (Groh et al., 1996; Bauer 
et al., 1999, Groh et al., 2001; Cerwenka et al., 2001; Moretta etal., 2000; Moretta etal., 2001; 
Lanier, 2005). 
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Figure (13): Missing-self hypothesis. The balance of inhibitory and stimulatory signals 
received by a natural killer cell determines the outcome of its interaction with a target cell. In 
case of NK cells interacting with target cells expressing ligands for both inhibitory and 
activating receptors, the outcome is determined by the summation of the strength of signals 
(Lanier, 2005). 
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1.5.1 Natural killer cell receptors 
 
1.5.1.1 Inhibitory receptors 
 
In human NK cells, both MHC class I molecule-specific (Moretta et al., 1996; Lanier, 1998; 
Long, 1999; Moretta et al., 2000) and non-classical MHC class I molecule-specific inhibitory 
receptors have been identified (Poggi et al., 1995; Meyaard et al., 1997; Cantoni et al., 1999; 
Falco et al., 1999; Moretta et al., 2000). Furthermore, the inhibitory receptors specific for 
HLA-class I belong to two structurally distinct families of molecules: the killer cell Ig-like 
receptors (KIR) and the killer cell lectin-like receptors (KLR). These inhibitory receptors 
prevent killing of normal cells and limit the production of inflammatory cytokines such as 
TNF-, GM-CSF and IFN-. Since surface expression of HLA-class I molecules is changed 
in response to malignant transformation (Garrido et al., 1997; Moretta et al., 2000) or viral 
infection of the cells (Biron, 1997; Zeidler et al., 1997, Ploegh, 1998; Cohen., 1999; Moretta 
et al., 2000), the most important role of HLA-class I specific inhibitory receptors is to check 
the integrity of potential target cells and thereby prevent damage of normal tissues. 
 
The inhibitory receptors include members of the KIR (Humans) and Ly49 (Mice) family 
which interact with MHC class I molecules as well as the killer cell lectin-like receptor (KLR) 
CD94/NKG2A which binds to non-conventional MHC I
b
 molecules (HLA-E in humans and 
Qa- I
b
 in mice) (Yokoyama, 1993;  Lanier; 1998; Lanier, 2005; Raulet and Vance, 2006). 
 
These inhibitory receptors signal via immunoreceptor tyrosine-based inhibitory motifs 
(ITIM). Upon receptor ligation, tyrosine residues in the ITIM domain (I/V/L/SxYxxL/V) are 
phosphorylated which enables them to interact with cytosolic Src-homology (SH2) domain-
containing proteins such as SHP-1 which are thus recruited to the inhibitory receptor 
complex. This leads to considerable changes in gene expression and stops activating signals 
that might otherwise lead to cytokine release and cytotoxic effector activity (Lanier, 1998; 
Tomasello et al., 2000; Moretta et al., 2000; Lanier, 2005). 
 
 
 
 
 
36 
 
1.5.1.2 Activating NK receptors 
 
In humans, several activating receptors expressed by NK cells (including NKp30, NKp44, 
NKp46, NKp80, NKG2D, DNAM-1, CD2, CD16 and 2B4) are responsible for cytotoxic 
activity of NK cells against transformed and virally infected cells (Moretta et al, 2000; 
Moretta et al, 2001; Lanier, 2005). 
 
The first triggering NK receptors were found based on the screening of mAbs able to induce 
NK-mediated killing of Fc-receptor positive tumour target cells in a redirected killing assay 
(Moretta et al, 2001). 
 
Natural cytoxicity receptors (NCRs) are selectively expressed by natural killer cells.  NKp46 
and NKp30 are expressed by resting and activated NK cells whereas NKp44 is expressed by 
activated NK cells only (Vitale et al., 1998; Moretta et al, 2000; Moretta et al, 2001). NKp80 
is expressed by NK cells that are freshly isolated from peripheral blood as well as by a small 
T cell subset characterized by the CD3
+
D56
+
 surface phenotype (Moretta et al, 2001). Upon 
crosslinking, NCRs mediate NK-cell activation, leading to the killing of target cells and to 
cytokine production (Moretta et al, 2000; Moretta et al, 2001). The ligands for NKp46 and 
NKp44 are yet unidentified (Moretta et al, 2000; Moretta et al, 2001; Lanier, 2005), whereas 
the ligand for NKp80, activation-induced C-type lectin (AICL), was described a few years 
ago (Welte et al., 2006; Thomas et al., 2008).  Likewise, nuclear factor HLA-B associated 
transcript 3 (BAT3) was identified as an activating ligand for NKp30 (Pogge von Strandmann 
et al., 2007; Simhadri et al., 2008). Still, it appears possible that further ligands may be 
discovered. 
 
NKG2D is one of the activating receptors expressed on NK cells, γδ T cells, CD8+ T cells and 
a small subset of CD4
+
 T cells. It is encoded by the killer cell lectin-like receptor subfamily 
K, member 1 gene (KLRK1) (Bauer et al., 1999; Moretta et al, 2000; Moretta et al, 2001; 
Lanier, 2005). The NKG2D receptor recognizes cell surface glycoproteins that are structurally 
related to MHC class I. These ligands, however, are not encoded by genes in the MHC 
complex and are stress-inducible molecules expressed on the tumour cells and virally infected 
cells. Human NKG2D ligands include MICA, MICB and ULBP1-6; while mouse NKG2D 
ligands include RAE-1, H60 and MULT1 molecules (Moretta et al, 2000; Moretta et al, 2001; 
Lanier, 2005). 
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DNAM-1 (CD226) is one of the triggering receptors that are not restricted to NK cells only, 
but also expressed on T cells, B cells, monocytes, and platelets (Burns et al., 1985; Scott et 
al., 1989; Shibuya et al., 1996; Moretta et al, 2001; Lanier, 2005). The ligands of DNAM-1 
receptor are CD112 (Polio virus receptor, PVR) and CD155 (Nectin-2) (Bottino et al., 2003; 
Tahara-Hanaoka et al., 2004; Lanier, 2005). Ligation of DNAM-1 by its ligand expressed on 
tumour cells provides a potent trigger for NK cell–mediated cytotoxicity and cytokine 
production (Masson et al., 2001; Bottino et al., 2003; Tahara-Hanaoka et al., 2004; Lanier, 
2005). 
 
2B4 (CD244) is another activating NK cell receptor and a member of the CD2 subfamily the 
members of which mainly functions as co-receptors rather than as true receptors. However, 
they can greatly enhance cytotoxic effector functions when co-engaged with a triggering 
receptor. 2B4 is expressed on human and mouse NK cells, γδ T cells, and CD8+ T cells 
(Moretta et al, 2000; Moretta et al, 2001; Smyth et al., 2002; Lanier, 2005; Sinha et al., 2010). 
The triggering function of 2B4 on NK cells becomes evident upon ligation with its ligand 
CD48 when it is simultaneously co-engaged with triggering receptors (Moretta et al, 2000; 
Moretta et al, 2001; Smyth et al., 2002; Lanier, 2005; Raulet and Vance, 2006). Nevertheless, 
2B4 may play a role as both inhibitory or stimulatory receptor, depending on the further 
receptors involved and on the associated signaling molecules in the respective cell type 
(Raulet and Vance, 2006). Since CD48 is expressed on the majority cells of hematopoietic 
cells, 2B4 on NK cells has the potential to interact with different cell types, including other 
NK cells. Thus, studies exploring the function of 2B4 in IL-2–propagated NK cells gave 
rather ambiguous results (Sinha et al., 2010). 
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2  Material and Methods 
2.1  Material 
2.1.1 Devices 
Device Manufacturer or distributor 
ABI TaqMan 7500 Applied Biosystems, Life Technologies 
Corporation, Carlsbad, California 92008, 
USA 
Agarose gel electrophoresis apparatus MupiD-exU, Eurogentec GmbH, Cologne,  
Germany 
Autoclave H P Labortechnik AG, 85764 
Oberschleißheim, Germany 
Balance Sartorius AG, 37075 Goettingen, Germany  
Centrifuges Eppendorf, 22339 Hamburg, Germany  
Jouan/Thermo Electron GmbH, 63303 
Dreieich, Germany 
CO2 Incubator Thermo Electron GmbH, 63303 Dreieich, 
Germany 
Counting chamber  Carl Roth GmbH + Co. KG 76185 Karlsruhe, 
Germany 
Cryo box Nalgene, Thermo Fisher Scientific, 63505 
Langenselbold, Germany 
Digital camera Canon, USA 
ELISA-Reader Sunrise TECAN, 74564 Crailsheim, Germany 
FACSCalibur Becton Dickinson, Franklin Lakes, NJ 
07417, USA 
Freezers  (-20°C, -86°C) Liebherr, Germany ; Thermo Electron GmbH 
39 
 
63303 Dreieich, Germany 
Philipp Kirsch GmbH. 77608 Offenburg, 
Germany 
Heating block  Biometra GmbH, D-37079 Goettingen,  
Germany 
Hot water bath Julabo, 77960 Seelbach, Germany 
Ice machine Scotsman Ice Systems, Vernon Hills, IL 
60061, USA 
Inverted Microscope Leica, 35606 Solms, Germany 
Irradiation machine Philips Electronics, Germany 
Laminar flow hood Heraeus, Hanau, Germany 
Liquid nitrogen tank Air Liquide, 40235 Düsseldorf, Germany 
Luminometer Orion II   Berthold Detection Systems, Germany   
MACS™ Separators Miltenyi Biotec GmbH, 51429 Bergisch 
Gladbach, Germany 
 
Magnetic stirrer VWR, 64295 Darmstadt, Germany 
Microwave Sharp Electronics (Europe) GmbH, Germany 
Olympus IX-70 Inverted System Microscope  Olympus, 20097, Hamburg 
PCR thermocycler Biometra GmbH, D-37079 Goettingen,  
Germany 
pH-Meter Mettler-Toledo GmbH, 35353 Gießen, 
Germany 
Photometer  Thermo Electron GmbH, 63303 Dreieich, 
Germany 
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Pipettes Eppendorf AG, 22339 Hamburg, Germany 
Power-Supply  Thermo Electron GmbH, 63303 Dreieich, 
Germany 
Refrigerator Liebherr, Germany 
Roller mixer  Stuart, Bibby Scientific Limited, Beacon 
Road, Stone, Staffordshire ST15 0SA, UK 
Sample shaker (Vortex) VWR, 64295 Darmstadt, Germany 
SDS gel electrophoresis system Whatman, GE Healthcare, D-80807 Munich, 
Germany 
Shakers Heidolph Instruments GmbH & Co. KG, 
91126 Schwabach, Germany 
Thermo-mixer  Eppendorf AG, 22339 Hamburg, Germany 
Ultra Freezer (-86°C)   Heraeus, Hanau, Germany 
UV lamp  Biometra GmbH,  D-37079 Goettingen,  
Germany 
X-ray film Cassettes  Carl Roth GmbH + Co. KG, 76185 
Karlsruhe, Germany 
 
2.1.2 Consumables 
Consumables Manufacturer or distributor 
 
X-ray films 
 
Fisher Scientific GmbH - Im Heiligen Feld 
17 - D-58239 Schwerte, Germany 
21-gauge needle Becton Dickinson, Franklin Lakes, NJ 
07417, USA 
Cell culture dishes TPP, 8219 Trasadingen, Switzerland 
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Cell culture flasks (25 cm
2
, 75 cm
2
) Greiner bio-one,  72636 Frickenhausen, 
Germany 
Cell culture plates (96-well, 24-well, 12-well, 
6-well 
TPP, 8219 Trasadingen, Switzerland 
Cryotubes Nunc, Roskilde, Denmark 
FACS tubes Hartenstein,  97078 Würzburg, Deutschland 
Falcon tubes (15 ml, 50 ml) Greiner bio-one,  72636 Frickenhausen, 
Germany 
Film (TaqMan)                                                                                                         Sarstedt, 51588 Nürmbrecht, Deutschland 
Gloves Cardinal Health, 7000 Cardinal Place, 
Dublin, OH 43017, Ireland 
Injection cannula B. Braun Melsungen, Pfieffewiesen  34212 
Melsungen, Germany 
KODAK developer KODAK 
KODAK fixer KODAK 
LS columns Miltenyi Biotec GmbH, 51429 Bergisch 
Gladbach, Germany 
Luminometer plates Greiner bio-one,  72636 Frickenhausen, 
Germany 
Micro test tubes (Eppendorf caps) Greiner bio-one,  72636 Frickenhausen, 
Germany 
Microtiter plates (Maxisorp) Nunc, Roskilde, Denmark 
Nylon Cell Strainer 70µm Becton Dickinson, Franklin Lakes, NJ 
07417, USA 
Parafilm Pechiney, 8770 W. Bryn Mawr Ave. 
Chicago, IL  
PCR tubes (8-Stripes, 96-well  
plate ABITaqMan-Platte) 
Sarstedt, 51588 Nürmbrecht, Deutschland 
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Perfusor syringe B. Braun Melsungen, Pfieffewiesen  34212 
Melsungen, Germany 
Petri dishes Carl Roth GmbH + Co. KG, 76185 
Karlsruhe, Germany 
Pipette tips (10 µl, 100µl, 100µl) Sarstedt, 51588 Nürmbrecht, Deutschland  
PVDF membrane Carl Roth GmbH + Co. KG, 76185 
Karlsruhe, Germany 
 
2.1.3 Cell lines 
Cell line Species Origin 
OaW-42 Human, OvCa European Collection of Cell 
Cultures (ECACC) 
OVCAR-3 Human, OvCa ATCC Manassas, VA 20110-
2209, USA 
PA1 Human, OvCa ATCC Manassas, VA 20110-
2209, USA 
RPMI 8866 Human, lymphoma ATCC Manassas, VA 20110-
2209, USA 
SKOV-3 Human, OvCa ATCC Manassas, VA 20110-
2209, USA 
K562 (pCDNA3.1-fluc)    Human erythroleukemic Dr. Ruth Seggewiß, 
Department of Internal 
Medicine, University of 
Würzburg 
 
2.1.4 Plasmid 
Plasmid Gene expression Origin 
CMV-fluc Firefly-luciferase Dr. Michael Jensen (City of 
Hope national medical center 
and Beckman Research 
Institute, Duarte, Ca, USA). 
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2.1.5 General reagents for cell culture 
Media , solutions and media additives Manufacturer or distributor 
Dimethylsulfoxid (DMSO) Carl Roth 
Dulbecco‟s PBS PAA 
Fetal calf serum (FCS) PAA 
Penicillin/Streptomycin PAA 
RPMI 1640 PAA 
 
Buffers and solutions Composition 
50 x TAE 2 M Tris, 0.6 M EDTA, 0.57% glacial acetic acid 
6 x DNA- loading buffer 30% Glycerin, 50 mM EDTA, 0.001% bromophenol blue 
FACS-Buffer     PBS, 2% FCS 
Freezing medium 70% FCS, 20% standard medium, 10 % DMSO 
MACS-Buffer PBS pH 7.2, 0.5% BSA, 2 mM EDTA 
PBA PBS, 1% BSA 
PBS 37 mM NaCl, 2.7 mM KCl, 80 mM Na2HPO4, 1.8 M 
KH2PO4, pH 7.4 
 
PBS-T PBS, 0.05% Tween20 
 
Standard medium 88.5% RPMI 1640, 10% FCS, 1% P/S 
TBS 10 mM Tris-HCl, 150 mM NaCl, pH 7.5 
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2.1.6 Buffers for polyacrylamide gels 
Gel Composition 
Separating gel 10%   
 
dd H2O 1.9 ml, Acrylamid/Bisacrylamid (30%) 1.7 ml  , 
Tris-HCl 1.5 M, pH 8.8 1.3 ml , SDS (10%) 50 µl, APS 
(10%) 50 µl, TEMED 2 µl 
Stacking gel 5%  
 
dd H2O 0.68 ml, Acrylamid/Bisacrylamid (30%) 0.17 ml, 
Tris-HCl 1 M, pH 6.8 0.13 ml, SDS (10%) 10 µl, APS 
(10%) 10 µl, TEMED 1 µl  
 
2.1.7 Buffers for SDS-PAGE and Western blot 
Buffer  Composition 
Blocking Buffer   
 
5% skim milk powder in PBS-T 
ECL solution A 50 mg Luminol in 200 ml 0.1 M Tris-HCl pH 
6.8 
ECL solution B 11 mg para- hydroxycoumarinic acid in 10 
ml of DMSO 
Lysis buffer                                                                                                                                            50 mM Tris-HCl, pH 8, 120 mM NaCl, 5mM
EDTA, 0.5% NP-40, 2 µg/ml, Aprotinin, 
10µg/ml Leupeptin, 100 µg/ml PMSF, 50 
mM NaF, 200 µM NaVO5 
Neutralization Buffer   1.5 M Tris-Base pH 7.4 
PBS-T PBS, 0.05% Tween20 
Ponceau S solution 0.2% Ponceau S in 3% trichloroacetic acid 
Protein loading buffer (5x) 100 mM Tris-HCl pH 6.8, 4% SDS, 0.2%  
Bromophenol blue, 20% Glycerol, 10% β-
Mercaptoethanol  
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Running buffer 25 mM Tris. 193 mM Glycin, 0.5% SDS pH 
8.8 
Stripping Buffer  0.2 M Glycin, 0.5 M NaCl, pH 2.8 
Transfer buffer  25 mM Tris, 192 mM Glycin, 20% Methanol 
2.1.8 Reagents for FACS staining  
Reagent Manufacturer or distributor 
Beriglobin solution Novartis 
FACS Clean Becton Dickinson 
FACS Flow Becton Dickinson 
FACS Rinse Becton Dickinson 
Monensin BioLegend 
 
2.1.9 Detachments 
Reagent Manufacturer or distributor 
Accutase PAA 
Trypsin EDTA PAA 
 
2.1.10 Kits 
Kit Manufacturer or distributor 
ABsolute Blue QPCR SYBR Green low Rox 
mix 
Thermo Fisher Scientific 
CD90.2 MicroBeads Kit MiltenyiBiotec 
Cell Proliferation Reagent WST Roche 
Cortisol luminescent immunoassay IBL 
Crimson longAmp Polymerase Kit                               New England Biolabs 
iScript cDNA Synthesis Kit Biorad 
MACS NK Cell Isolation Kit II MiltenyiBiotec 
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2.1.11 Disinfectant 
Disinfectant Manufacturer or distributor 
Cutasept Bode 
Ethanol (EtOH)   Hospital pharmacy 
 
2.1.12 Cytokine 
Cytokine Concentration Manufacturer or 
distributor 
IL2 100 U/ml PeproTech 
TGF-β 5 ng/ml PeproTech 
 
2.1.12 Virus 
Virus Source 
AdCre virus University of Iowa GeneTransfer Vector 
Core 
 
2.1.13 Oligonucleotides 
Oligonucleotide 
 
Origin Sequence 5´ -> 3´ 
18s RNA, forward Sigma CGGCTACCACATCCAAGGAA 
18s RNA, reverse Sigma GCTGGAATTACCGCGGCT 
GAPDH, forward Eurogentec ACGACAGTCCATGCCATCAC 
GAPDH, reverse  Eurogentec TCCACCACCCTGTTCCTGTA 
h11-HSD1, forward Sigma ATTCACCATGTGCGCAAAAG 
h11-HSD1, reverse Sigma GGAGACGACAACAATGCTTCC 
h11-HSD2, forward Sigma GGGCCTATGGAACCTCCAA 
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h11-HSD2, reverse Sigma GACCCACGTTTCTCACTGACTCT 
h2B4, forward Sigma ACAAAAGGCCACATTCCAAG 
h2B4, reverse Sigma AACCCAGAGAGGGGAGAAAA 
hCD2, forward  Sigma CCAGCCTGAGTGCAAAATTCA 
hCD2, reverse Sigma GACAGGCTCGACACTGGATTC 
hDNAM-1, forward Sigma GCAGTGACCAAGAGGGTGTT 
hDNAM-1, reverse Sigma CTGCTCGCTCTAACGCTTCT 
hNKG2D, forward  Sigma TCTCGACACAGCTGGGAGATG 
hNKG2D, reverse  Sigma GACATCTTTGCTTTTGCCATCGTG 
hNKp30, forward  Sigma TGTCCTGAGAAATGGGAAGG  
hNKp30, reverse Sigma ACAGTGTTCAGGGACCCAAG 
hNKp46, forward  Sigma ACAACCATGCCTGGTCTTTC 
hNKp46, reverse Sigma AAAAGGTAGCGTGCCCCAAGT 
m11-HSD1, forward Sigma GTCCCTGTTTGATGGCAGTT 
m11-HSD1, forward Sigma TTATGAAAAAATACCTCCTCCC 
m11-HSD1, reverse Sigma GCCCCAGTGACAATCACTTT 
m11-HSD1, reverse Sigma CTTTGATCTCCAGGGCGCATTC 
mGR, forward  Sigma GTGAGTTCTCCTCCGTCCAG 
mGR, reverse Sigma TACAGCTTCCACACGTCAGC 
mIL-1α, forward Sigma CAAACTGATGAAGCTCGTCA 
mIL-1α, reverse Sigma TCTCCTTGAGCGCTCACGAA 
mIL-1β, forward Sigma CTGTGTCTTTCCCGTGGACC 
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mIL-1β, reverse Sigma CAGCTCATATGGGTCCGACA 
mKras dt5 new Sigma GTCGACAAGCTCATGCGGG 
mKras SD5 new (5 Mut) Sigma CCATGGCTTGAGTAAGTCTGC 
mKras Uni new(3 Universal) Sigma CGCAGACTGTAGAGCAGCG 
mMMP-9, forward  Sigma CGGCACGCTGGAATGATC 
mMMP-9, reverse Sigma TCGAACTTCGACACTGACAAG 
mPten6637, forward Sigma TCCCAGAGTTCATACCAGGA 
mPten6925,reverse Sigma GCAATGGCCAGTACTAGTGA 
mPten7319,reverse Sigma AATCTGTGCATGAAGGAAC 
mTNF-α, forward Sigma GGGCCACCACGCTCTTC 
mTNF-α, reverse  Sigma GGTCTGGGCCATAGAACTGAT 
 
2.1.13 Chemicals, solutions and reagents  
Chemicals, solutions and reagents Manufacturer or distributor 
ACD-A (sodium citrate solution) Haemonetics 
Acetone Carl Roth 
Acrylamid/ Bisacrylamid   Carl Roth 
Agarose Carl Roth 
Ammonium persulfate (APS) Carl Roth 
Aprotinin Carl Roth 
Aqua ad iniectabilia Braun 
Biocoll separation solution Biochrom 
Bovines Serum Albumin (BSA)   Applichem 
Bromophenol blue Carl Roth 
Chloroform Sigma 
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Cortisol Rotexmedica 
Diaminobenzidine (DAB) Dako 
Dispase Roche 
Ethylenediaminetetraacetic acid (EDTA) Applichem 
GelRed Biotium 
Glacial acetic acid Carl Roth 
Glycerin Carl Roth 
Glycin Carl Roth 
Goat serum Caltag 
Haematoxylin Carl Roth 
Human serum albumin (HSA)    Behring 
Hydrochloric acid Applichem 
Hydrogen peroxide   Carl Roth 
Ionomycin Cayman 
Isopropanol   Carl Roth 
Leupeptin Carl Roth 
Luciferin P.J.K. 
Luminol salt Sigma 
Methanol Hospital pharmacy 
NP-40 Applichem 
PeqGold Trifast  Peqlab 
Phenylmethanesulfonylfluoride  (PMSF) Carl Roth 
Phorbol 12-myristoyl 13-acetate (PMA) Sigma 
Phospho-Stop (tablets) Roche 
Ponceau S Carl Roth 
Potassium (di) hydrogen phosphate Carl Roth 
Potassium chloride Carl Roth 
50 
 
Roti-Quant   Carl Roth 
Skimmed milk powder   Merck 
Sodium (di) hydrogen phosphate Carl Roth 
Sodium chloride Carl Roth 
Sodium dodecyl sulfate (SDS) Carl Roth 
Sodium fluoride Applichem 
Sodium hydroxide Carl Roth 
Sodium orthovanadate Applichem 
Streptavidin-HRP Dako 
Tetramethylethylenediamine (TEMED) Carl Roth 
Trichloroacetic acid Carl Roth 
Tris hydroxymethyl aminomethan (Tris)-
Ultra   
Carl Roth 
Tris-HCl   Carl Roth 
Tween20 Carl Roth 
Vitro Clud Langenbrinck 
β-Mercapthoethanol   Carl Roth 
 
2.1.14 Standard DNA and protein ladder 
TriDye™ 2-Log DNA Ladder (0.1 - 10.0 kb)                                       Thermo Fischer 
Scientific New England Biolabs 
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2.1.15 Antibodies  
 
 
Antibody Species Label Dilution Source Clone or 
Catalog No. 
Anti- human 11-HSD1 Rabbit Purified 1:50 Abcam ab39364-100 
Anti- human 11-HSD2 Rabbit Purified 1:50 Biotrend BHSD23-A 
Anti- human CD14 Mouse Purified 1:50 Dako TÜK4 
Anti- human CD68 Mouse Purified 1:50 AbD Serotec 514H12 
Anti- human CD85 Mouse Purified 1:50 Dako VMP55 
Anti- human EpCAM Mouse Purified 1:50 MiltenyiBiotec HEA-125 
Anti- human GR  Rabbit Purified 1:1000 Santa Cruz Sc-8992 (H-
300) 
Anti- sheep IgG (Secondary 
antibodies) 
Rabbit HRP 1:5000 Santa Cruz Sc- 2770 
Anti-human 2B4 Mouse Purified 1:500 BioLegend C1.7 
Anti-human CD107a                                                   Mouse PE 1:20        BioLegend H4A3 
Anti-human CD2 Mouse PE 1:100                                                                                                                                        MiltenyiBiotec LT2
Anti-human CD3    Mouse PE 1:100 ImmunoTools MEM-57 
Anti-human CD3    Mouse FITC 1:100 ImmunoTools MEM-57 
Anti-human CD56  Mouse APC 1:250   Beckman 
Coulter 
N901 
Anti-human DNAM-1 Mouse FITC 1:100                                                                                                                                        eBioscience 11A8
Anti-human IgG1-isotype Mouse FITC 1:100 BioLegend MOPC-21 
Anti-human IgG1-isotype Mouse PE 1:100 BioLegend MOPC-21 
Anti-human NKG2D   Mouse Purified 1:500 BioLegend 1D11 
Anti-human NKG2D   Mouse PE 1:100 MiltenyiBiotec BAT221 
Anti-human NKp30 Mouse PE 1:100 MiltenyiBiotec AF-29-4D12 
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Anti-human NKp44 Mouse PE 1:100 MiltenyiBiotec 2.29 
Anti-human NKp46 Mouse PE 1:100 MiltenyiBiotec 9E2 
Anti-mouse 11-HSD1 Rabbit Purified 1:50 Cayman 10004303 
Anti-mouse 11-HSD2 Sheep Purified 1:50 Chemicon AB1296 
Anti-mouse CD4 Rat Purified 1:50 ImmunoTools YTS 191.1.2 
Anti-mouse CD45.1 Mouse PE 1:100 BioLegend A20 
Anti-mouse CD45.2                                    Mouse FITC 1:100 BioLegend 104 
Anti-mouse DCIR2 Rat Biotin 1:50 MiltenyiBiotec 33D1 
Anti-mouse EpCAM Rat Biotin 1:1000 BioLegend G8.8 
Anti-mouse FOXP3 Mouse APC 1:50 MiltenyiBiotec 3G3 
Anti-mouse IgG (Secondary 
antibodies) 
Donkey Alexa 488 1:50 Invitrogen  A-21202 
Anti-mouse –IgG 
(Secondary antibodies) 
Horse HRP 1:5000 Cell signaling 
 
#7076  
Anti-mouse Pten Rabbit Purified 1:1000 Epitomics EP229 
Anti-mouse -actin Mouse Purified 1:1000 Abcam Ab8226 
Anti-Rabbit IgG (Secondary 
antibodies) 
Goat HRP 1:5000 Cell signaling 
 
#7074 
Anti-Rabbit IgG (Secondary 
antibodies) 
Goat Alexa 555 1:50 Invitrogen A-21428 
Anti-Rat IgG (Secondary 
antibodies) 
Goat HRP 1:5000 Cell signaling 
 
#7077 
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2.2 Methods 
2.2.1 Thawing of cells 
 
Cryopreserved cells were thawed quickly, resuspended in 1 ml of pre-warmed medium, 
transferred into a 15 ml tube containing 5 ml of pre-warmed medium and spun down for 5 
min at 1,500 rpm. The supernatant was aspirated using a Pasteur pipette. Then, the cell pellet 
was resuspended in 5 ml fresh medium and transferred into a 25 cm
2
 cell culture flask. During 
growth periods, the cells were cultured at 37°C/5% CO2 and 95% relative humidity in the 
incubator. 
 
2.2.2 Culturing and Sub-culturing of tumour cells 
 
 After growth in 25 cm
2
 tissue culture flasks, cells were transferred to 75 cm
2
 tissue culture 
flasks and cultured in 10 ml of medium at 37°C/5% CO2 and 95% relative humidity. Medium 
change and subculture were performed when cells became confluent every three to four days.  
For sub-culturing, the cells were washed once with PBS before being incubated with 1 ml 
Trypsin/EDTA or Accutase. After 5-10 min at 37°C, the cells were completely detached. 
Then, the action of trypsin/EDTA or Accutase was stopped with 5 ml of FCS-containing 
medium, the cells were collected and centrifuged at 1500 rpm for 5 min, resuspended in 10 ml 
of medium and cells were diluted 1 to 10 and transferred into a new cell culture flask for 
further cell culture. 
 
2.2.2 Cryopreservation of cells 
 
For long-term archiving, cells were stored in a liquid nitrogen tank. For cryopreservation, the 
cells were detached with Trypsin/EDTA or Accutase (as described above), centrifuged at 
1,500 rpm for 5 min and the cell pellet was taken up in 1 ml of fresh freezing medium. The 
cells were then placed for 24 h in a -80°C freezer equipped with special cryogenic boxes in 
which the temperature decreases by about 1°C/min. This enables a slow and gentle cell 
freezing to minimize cell death. After 24 h, the cells were transferred from the Cryobox into 
the liquid nitrogen tank. 
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2.2.3 Preparation and isolation of NK cells (Effector cells) 
2.2.3.1  Isolation of human peripheral lymphocytes from whole blood (McGuckin et al., 
2008) 
 
To obtain peripheral blood lymphocytes (PBL), blood was drawn from healthy donors. To 
prevent clotting, 10% of sodium citrate solution was added, e.g. 5 ml of sodium citrate 
solution for 45 ml of whole blood. All steps were performed under sterile conditions. The 
citrated blood was diluted with twice the amount of PBS and distributed into 50 ml centrifuge 
tubes which had already been filled with 15 ml Biocoll lymphocyte separation medium. 
Without mixing, the citrate blood-PBS mixture was gently poured on the Biocoll layer in 
order to obtain two phases. For the following density gradient centrifugation, the centrifuge 
had to be at room temperature without brake and with very low acceleration. First, the tubes 
were centrifuged at 600 rpm for 20 minutes before; the uppermost 5 ml were aspirated from 
each tube to remove the platelets. The following centrifugation run lasted 30 minutes at 1400 
rpm. Then, peripheral blood monocytes (PBMC) were ready to be collected from the 
interphase layer. 
 
 
 
 
 
 
 
       
               
              
 
             Figure (14): Scheme of the density gradient. 
                           
Left, before centrifugation: B = Blood-Citrate-PBS mixture 
                                             F = Biocoll Separation Solution 
Right, after centrifugation, P = Plasma, and platelets 
                                            W= PBMC layer 
                                            R= Biocoll above erythrocytes 
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The PBMC layers of all tubes were then collected by gentle aspiration with a 5 ml pipette and 
transferred into fresh 50 ml tubes. Care was taken in order to minimize the amount of biocoll 
solution transferred with the cells. Then, the cells were washed and centrifuged twice with 
PBS for 8 minutes at 1,800 rpm. Afterwards, the PBMC cell pellet was resuspended and the 
cell number was counted with trypan blue in a Neubauer counting chamber. Approximately 
50-60 million of these PBMCs were then resuspended in 10 ml of medium, placed in a cell 
culture dish and left to adhere for 1 h in an incubator. To obtain peripheral blood lymphocytes 
(PBL), the free floating cell fraction of was thereafter aspirated carefully while the cells that 
adhered to the floor of the cell culture dish represented mainly monocytes that could be used 
for other experiments. Typically, 20 -50 million PBL could be obtained from 50 ml of citrated 
blood. 
 
2.2.3.2 Preparation of polyclonal NK cell cultures (Perussia et al., 1987) 
   
Cultured RPMI 8866 feeder cells were irradiated with 30 Gy in a gamma irradiation facility 
(Neurological University Clinic Würzburg). Using 24-well plates, feeder cells and PBL were 
mixed in the ratio 1:4 in 500 µl RPMI medium per well and incubated for 8-14 days. On day 6 
of culture, 500 μl of fresh medium was supplemented to each well. Cytokines and growth 
factors produced from feeder cells stimulate the clonal expansion of NK cells. This was 
observed by cell-cluster formation. The obtained polyclonal NK cell cultures were used for 
experiments between day 8 and 11. The purity of the polyclonal NK cell cultures was 
determined by flow cytometric staining for surface markers CD3
-
/CD56
+
. 
 
2.2.3.3  Isolation of NK cells from whole blood by magnetically-activated cell sorting 
(MACS) technology  
 
PBL were isolated, counted and resuspended very well to obtain a single cell suspension 
before they were centrifuged again at 300 ×g and 8°C for 10 min. The labeling and separation 
of the cells was carried out according to instructions provided with the "NK cell isolation kit 
II" manufactured by Miltenyi. With this kit, all except the desired cells were labeled with 
biotinylated antibodies against the corresponding surface markers. Subsequently, iron-
containing anti-biotin beads were added to the biotinylated cell mixture. The labeled immune 
cells were loaded onto an LS column that was placed in a magnetic field in which the labeled 
immune cells were retained. The “untouched” fraction which passed through the column 
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consisted of the desired NK cells. After the column had been washed three times with MACS 
buffer, the purified cells were centrifuged at 1500 rpm for 5 min, counted and the purity was 
determined by flow cytometry staining for CD3
-
/CD56
+
 cells. 
 
2.2.4 Flow cytometric analysis of immune cells  
2.2.4.1  Extracellular FACS staining 
 
Surface marker expression of immune cells was determined by flow cytometric staining. Cells 
were transferred into FACS tubes and washed once with PBS. The non-specific binding sites 
for antibodies (Fc- receptors) were blocked with human IgG (Beriglobin) solution. After 
washing once in FACS buffer, immune cells were incubated for 30 min in the dark with 
fluorescence-labeled antibodies against the respective surface antigens. Appropriate antibody 
concentrations had been determined via titration. After washing twice in FACS buffer, the 
stained cells were resuspended in 100-150 μl of FACS buffer.  Flow cytometric analysis was 
performed on a FACS Calibur and evaluated using the Summit analysis program (Beckman 
Coulter, Version 4.3). 
 
2.2.4.2  Detection of CD107a (LAMP-1) at the cell surface (Alter et al., 2004) to measure 
degranulation 
 
Immune cells were isolated and treated for 72 h with 5 µM cortisol or 5 ng/ml TGF-β1 or 
both., As positive control, T cells were activated with 5 ng/ml PMA and 1µM Ionomycin. 
Then, CD107a antibodies (1:50 dilution) were added directly to the immune cells into the 
medium, followed by monensin (1:1000, 6µg/ml) to block the Golgi apparatus. Thereafter, 
cells were incubated for further 4 h at 37 °C, transferred to FACS tubes and washed twice 
with FACS buffer. For extracellular staining, the PBLs were blocked with Beriglobin solution 
at 4°C for 15 min before the surface markers CD3 and CD56 were counter-stained at 4°C for 
30 min in the dark. After washing twice in FACS buffer, the stained cells were resuspended in 
100-150 μl for flow cytometric analysis and analysed on a FACSCalibur. 
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2.2.5 Functional bioassays 
2.2.5.1 Treatment of immune cells with cortisol and TGF-β1 for functional assays 
 
Immune cells for functional experiments were isolated, seeded in 24-well plates at a density 
of 1-5 million of PBL or NK cells per ml of RPMI medium, treated for 72 h with 5 µM 
cortisol or 5 ng/ml TGF-β1 or both and then used for functional experiments. 
 
2.2.6 Determination of cell viability using WST-1 assay (Roche) 
 
The WST-1 assay is colorimetric assay designed to measure the relative metabolic activity of 
cells in culture. The assay is based on the reduction of the tetrazolium salt WST-1 into a 
colored dye by mitochondrial dehydrogenase enzymes. The soluble formazan salt is released 
into the medium. Within a certain time period, the reaction produces a color change which is 
directly proportional to the amount of mitochondrial dehydrogenase. As a result, the assay 
actually measures the net metabolic activity of cells which is a surrogate parameter for cell 
viability. From the cells that were left untreated or treated cells with cortisol or TGF-β1 or 
both, 10
4
 cells were seeded in 100 µl medium per well in a 96-well plate. Thereafter, 10 μl per 
well of WST1-reagent was added, then incubated for further 4 h at 37°C and absorbance was 
measured in the photometer at 450 nm (correction wavelength 620 nm).   
 
2.2.7 Lysis assay with K562-fLuc target cells (Brown et al., 2005) 
 
To assess cytotoxicity, polyclonal NK cells were prepared, treated or not with cortisol or 
TGF-β1 or both for 72 h and used between day 8 and day 10 as cytotoxic effector cells against 
K562 targets that had been stably transfected with a firefly luciferase plasmid. These K562 
fLuc target cells were seeded into opaque white 96-well plates, and NK cells were added in 
triplicates at the indicated E (ffector): T (arget) ratios. After addition of cell-permeable D-
luciferin (PJK) at 0.14 mg/ml, the cells were further incubated and luminescence was detected 
at various time points. The ATP-dependent conversion of luciferin occurs only in viable 
luciferase-transfected cells and is thus directly proportional to cell viability.  
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2.2.7.1  Restimulation experiment with cortisol or TGF- treated NK cells  
 
On day 8 of the preparation, polyclonal NK cells were treated or not with cortisol or TGF-β1 
or both for 72 h. Then, the NK cells were washed 2 times with fresh RPMI medium to remove 
the residues of cortisol or/and TGF-β1 before the differently pre-treated groups of washed 
cells were each divided again into 3 groups. First, cells with fresh medium only served as 
control group. In the second group, cells were co-cultured in fresh medium with MACSiBeads 
loaded with NKp46 and CD2 antibodies, using 5 µl (5×10⁵ loaded MACSiBeads) per 10⁶ NK 
cells. In the third group, cells were seeded in fresh medium onto plates that had been coated 
with antibodies against NKG2D and 2B4. Thereafter, all groups were incubated for further 48 
h and then used as effector cells in a killing assay against K562-fLuc target cells. 
 
2.2.8 Protein biochemical methods 
2.2.8.1 Preparation of cell lysates from tumour cells and tissues 
 
Five million tumour cells were centrifuged for 5 min at 450 x g at 4°C, then the cell pellet was 
washed with 100 µl of PBS to which protease and phosphates inhibitors (2 µg/ml aprotinin, 
10 µg/ml leupeptin, 100 µg/ml PMSF, 50 mM NaF, 200 µM NaVO5 and 1 x phospho-stop, 
respectively) had been added. Then, 70 µl of lysis buffer-P containing protease and 
phosphatase inhibitors were added to each sample and the cells were lysed on ice for 20 min. 
Thereafter, the protein lysates were centrifuged for 15 min at 13,000 ×g at 4°C and the 
supernatant was transferred into new caps. Subsequently, the total amount of protein was 
determined in this cell lysate. Tumour tissues that had been stored at -80°C were first minced 
with mortar and pestle under liquid N2 until they became a fine powder. Then, protein lysates 
were obtained using the same protocol as from tumour cells.  
2.2.8.2 Determination of the total amount of protein by the Bradford method 
 
To determine the total protein concentration in a cell lysate, the Bradford assay was 
performed. This is a colorimetric assay which is based on the property of the Coomassie 
Brilliant Blue dye to form complexes with proteins, thereby leading to a photometrically 
detectable colour shift. First,  50 µl of distilled water was loaded in every well of a 96-well 
plate, then 1 µl of protein lysate or Protein standard (HSA) was loaded in triplicate. For the 
standard row, protein concentrations of 1, 2, 4, 6, 8, 10 and 12 µg/ml were used. Thereafter, 
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Rotiquant Bradford reagent was diluted by 1:3.75 with distilled water, and then 200 µl of this 
solution were added to each well. After 20 min at room temperature, total protein 
concentration was determined in an ELISA reader by measuring the absorbance at 595 nm. 
 
2.2.8.3 Immunoblotting 
 
SDS- Polyacrylamide gels (containing between 8% and 15% of polyacrylamide) were 
prepared using a casting frame. For each sample, 20 µg of total protein lysate were mixed 
with the appropriate volume of reducing 5x Protein loading buffer and denatured for 5 min at 
95°C, then chilled on ice for 3 min. The gel chambers were filled with running buffer, 20 µg 
of denatured proteins were loaded into each pocket of the polyacrylamide gel and 8-10 µl of a 
prestained protein standard were used to determine the size of the other loaded proteins. The 
SDS-PAGE run was carried out at 90 V for 20 min to collect the protein in the stacking gel, 
then a further 100 min at 130 V to separate the proteins in the running gel. The proteins were 
electro- blotted on a PVDF membrane at 145 V for 85 min using transfer buffer. The quality 
of the transferred protein was checked with Ponceau S staining. Afterwards, the membrane 
was washed with distilled water for 5 min and de-stained with PBS-T buffer for 5 min. 
Unspecific binding was minimized by incubating the membrane in blocking buffer for 2 h at 
RT, thereafter the primary antibody was incubated at 4°C overnight. Typical antibody 
concentrations ranged from 0.5-2 µg/ml. After incubation with the primary antibody diluted in 
the blocking buffer, the membrane was washed three times for 10 min with PBS-T, then 
incubated with HRP-coupled secondary antibody diluted in the blocking buffer (1:5,000) and 
washed again with PBS-T three times for 10 min. The HRP activity was detected using a 
home-made chemiluminescence detection system consisting of 1 ml solution A (50 mg 
Luminol in 200 ml 0,1 M Tris-HCl pH 6.8), 100 µl solution B (11 mg para- 
hydroxycoumarinic acid in 10 ml of DMSO) and 0.3 µl H2O2. These were mixed and then 
incubated on the membrane for 2 min, chemiluminescence was detected using X-ray films 
that were developed with developer solution (KODAK Developer) for 3 min and fixed for 1 
min with fixative solution (KODAK Fixer). For re-probing, membranes were stripped with 
stripping buffer (0.2 M Glycin, 0,5 M NaCl, pH 2.8) for 10 min, followed by neutralization 
with neutralizing buffer (25 mM Tris 193 mM Glycin, 0,5% SDS pH 8.8) for 10 min. After 
further blocking, the membrane could then be incubated again with another antibody, e.g. a 
loading control like -actin.  
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2.2.9 Methods for analysis and manipulation of gene expression 
2.2.9.1 Isolation of RNA from tumour and immune cells 
 
For isolation of RNA from immune cells or tumour cells, 5x10
6
 cells were pelleted and 
treated with 1 ml TriFast reagent at room temperature for 5 min. Then, per 1ml TriFast 0.2 ml 
of chloroform were added to the sample, followed by shaking for 15 sec and further 
incubation for 5 min at room temperature. Thereafter, the mixture was centrifuged for 15 min 
at 12,000 ×g at 4°C and the upper aqueous phase containing the RNA was carefully 
transferred into a fresh vial. To precipitate the RNA, an equal amount of isopropanol was 
added to the aqueous phase and incubated for 10 min on ice, then centrifuged for 15 min at 
12,000 ×g at 4°C. The RNA pellet was washed twice with 75% EtOH. To precipitate the 
RNA after each wash, it was centrifuged for 5 min at 7,500 xg at 4°C. Then, the RNA pellet 
was dried in the air. The RNA pellet was finally dissolved in 30 µl of double deionized (dd) 
H2O. 
 
2.2.9.2 Determination of RNA concentration 
 
The RNA concentration was determined using a spectrophotometer. The RNA was diluted 
1:100 in (dd) H2O; the absorbance was measured at 260 and 280 nm against (dd) H2O water 
control. The concentration was calculated using the formula: C [μg / ml] = OD260 nm x dilution 
factor x 40 
The quality of the isolated RNA was estimated by dividing the value obtained for the 
absorbance at 260 nm by the absorbance measured at 280 nm. Ideally, the ratio OD260 
nm/OD280 nm should be 1.8. 
 
2.2.9.3 Synthesis of cDNA from isolated RNA (BioRad) 
 
iScriptTM cDNA Synthesis Kit was used for synthesis of cDNA from isolated RNA. This kit 
consists of a modified MMLV (Mouse Moloney Leukemia Virus)-derived reverse 
transcriptase with RNase H endonuclease activity, an RNase inhibitor and a blend of 
oligo(dT) and random hexamer primers. Oligo(dT) primers bind to the polyA-tail contained  
in all cellular mRNAs while random hexamers can bind within any given RNA sequence. 
After primer binding at 25°C, reverse transcription occurred during 30 min at 42°C in a PCR 
thermocycler. 
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Table (2): Composition of cDNA synthesis reaction. 
Component Volume 
5x iScript Reaction Mix 4 μl 
iScript reverse transcriptase 1 μL 
RNA template 0.5 ug 
Nuclease-free water to 20 μl 
 
Table (3): cDNA synthesis program steps. 
Temperature Incubation period 
25°C 5 min 
42°C 30 min 
85°C 5 min 
 
2.2.9.4 Reverse transcriptase Polymerase Chain Reaction (PCR)  
 
To qualitatively measure the expression level of mRNA transcripts, cDNA was used as 
template in PCR reactions. PCR reactions were performed using the Crimson longAmp 
Polymerase Kit and a PCR thermocycler. 
 
Table (4): Composition of the PCR reaction. 
Component Volume 
5 x Crimson LongAmp Taq Buffer          5 μl 
10 mM dNTP                                                        0.75 μl 
100 µM forward primer                                    1 μl of 1:10 diluted primer 
100 µM reverse primer                                      1 μl of 1:10 diluted primer 
cDNA 1 μl 
(dd) H20 to 25 μl 
AmpliTaq Polymerase 0.5 μl 
 
62 
 
Table (5): The program steps for PCR Reaction 
Temperature Incubation time 
94°C 3 min 
94°C 30 sec 35 cycles 
Primer-dependent annealing temperature 
(e.g. 60 °C) 
30 sec 35 cycles 
72°C 45 sec 35 cycles 
72°C 10 min 
4°C Hold 
 
2.2.9.5 Polymerase Chain Reaction (PCR) For Mouse genotyping 
2.2.9.5.1 Isolation of genomic DNA from mouse ear punches (Truett et al., 2000) 
 
Mouse ear punches were treated with 100 µl of a mixture containing 25 mM NaOH and 0.2 
mM EDTA (pH 8) and placed for 60 min at 95°C in a heating block. Then, 100 µl of 40 mM 
Tris HCl (pH 5.5) were added and the sample was spun down at 4,000 rpm for 3 min. The 
supernatant which contains the genomic DNA was transferred to a fresh vial. For genotyping, 
about 1µl from this supernatant was used. 
 
2.2.9.5.1.1 Kras genotyping 
 
Table (6): Composition of the PCR reaction for Kras genotyping. 
Component     Stock   Volume 
Crimson LongAmp Taq Buffer          5x 5µl 
dNTP   10 mM 0.75µl 
dt5-Primer                                          100µM → 
1:2.5 
0.6µl 
Uni-Primer                                          100µM → 
1:2.5       
0.4µl 
SD5-Primer                                          100µM → 
1:2.5         
0.2µl 
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gDNA  1µl 
(dd) H20   to 25µl 
Crimson LongAmp Taq DNA 
Polymerase 
 0.5µl 
 
Table (7): The program steps for Kras PCR Reaction. 
Temperature Incubation time 
94°C 3 min 
94°C 30 sec 35 cycles 
64°C 1 min 30 sec 35 cycles 
72°C 1 min 35 cycles 
72°C 5 min 
4°C Hold 
 
PCR product size: 
 wt 500bp 
 loxP-Stop-loxP-KrasG12D 550bp 
 
 
2.2.9.5.1.2 Pten genotyping 
 
Table (8): Composition of the PCR reaction for Pten genotyping. 
Component     Stock   Volume 
Crimson LongAmp Taq Buffer          5x 5µl 
dNTP   10 mM               0.75µl 
Pten 6637-F Primer                                          100µM 0.25µl 
Pten 6925-R Primer                                          100µM 0.25µl 
Pten 7319-R Primer                                          100µM 0.25µl 
gDNA  1µl 
(dd) H20  to 25µl 
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Crimson LongAmp Taq DNA 
Polymerase 
 0.5µl 
Table (9): The program steps for Pten PCR Reaction. 
Temperature Incubation time 
94°C 3 min 
94°C 45 sec 40 cycles 
60°C 30 sec 40 cycles 
72°C 1 min 40 cycles 
72°C 5 min 
4°C Hold 
 
PCR product size: 
 wt 500bp 
 loxP-Pten-loxP 650bp 
 del ex5 300bp 
 
2.2.9.5.2 DNA gel electrophoresis 
 
For analysis of PCR products, 1% agarose gels were prepared in 1 x TAE buffer stained with 
3 µl of GelRed. Thereafter, 10-20 µl of PCR product mixed with 2 µl 6 x DNA loading buffer 
were loaded and the gels were run in 0.5 x TAE buffer for 1 h at 90 V. To determine the size 
of the PCR product, a standard 100 bp DNA ladder was loaded on the gel. The separated 
DNA bands were visualized by UV light and documented with a digital camera.   
 
2.2.9.5.3 Semi-quantitative real time PCR 
 
For relative quantification of mRNA transcript levels, real time PCR (qRT-PCR) was applied. 
To this aim, the genes of interest were amplified from the synthesized cDNA using the 
ABsolute Blue QPCR SYBR Green low Rox mix kit for qRT-PCR. The purity of the PCR 
products was assessed via the dissociation curve. The samples were used in duplicates and 
only used when the deviation of Ct-values was ≤ 0.5 cycles. (In a real time PCR assay, the Ct 
(cycle threshold) value is defined as the number of cycles required for the accumulating 
65 
 
fluorescent signal to cross the threshold, i.e.  to exceed background level. Ct levels are 
inversely proportional to the amount of target nucleic acid in the sample which means that a 
low Ct level corresponds to a relatively large amount of target nucleic acid in the sample.) The 
relative expression of mRNA was quantified relative to the expression of the 18S rRNA and 
with the expression of untreated control or healthy control and calculated according to the 
ΔΔCt method, using the formula rI= 2
[(C
t
gene of interest, investigated sample – C
t
18S investigated sample) - (C
t
gene of 
interest, reference sample – C
t 
18S reference sample)]. 
 
Table (10): Composition of the qRT-PCR reaction. 
Component       Volume 
2 x ABsolute Blue QPCR SYBR Green low 
Rox mix 
7.5 μl 
Forward primer (1:90 diluted in (dd) H20) 1 μl 
Reverse primer ( 1:90 diluted in (dd) H20) 1 μl 
Water for injection 0.5 μl 
cDNA (1:20 in water for injection)   5 μl 
 
Table (11): The program steps for qRT-PCR reaction were performed in the ABI 
TaqMan 7500. 
Temperature Incubation time 
50°C                      2 min 
95°C 15 min 
95°C 15 sec 40 cycles 
60°C                     1 min 40 cycles 
95°C                15 sec dissociation curve 
60°C                        1 min 
95°C                    15 sec 
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2.2.10 Immunohistochemical staining 
 
All human tissue specimens were provided by the tumour bank of the University Hospital 
Würzburg. Mouse tissue specimens were collected from the animal facility in the Institute for 
Virology and Immunobiology (Würzburg University, Germany). Frozen tissue samples were 
cut at 4 µm, fixed in an ice-cold acetone/methanol mixture (1:1) for 5 min and rehydrated in 
TBS buffer for 15 min. The non-specific binding to tissue antigens was blocked with 10% 
normal goat serum in TBS buffer for 30 min, and endogenous peroxidases were left to react 
with 3% H2O2. After washing with TBS buffer for 10 min, the slides were incubated 
overnight with diluted primary antibody. Following 3 washes with TBS buffer for 5 min, the 
slides were incubated for 1 h with a secondary biotinylated antibody, then washed again 3 
times with TBS buffer for 5 min followed by HRP-conjugated streptavidin for 30 min - 1 h. 
Stainings were developed with diaminobenzidine for 15 min. Nuclei were counterstained with 
haematoxylin. Stained sections were then dehydrated by washing in graded ethanol and 
embedded in Vitro-Clud. 
 
2.2.11 Cortisol levels in serum and ascitic fluid 
2.2.11.1 Cortisol luminescent immunoassay (LIA) 
 
Cortisol concentrations were determined in serum and ascitic fluid of ovarian cancer patients 
by a luminescent immunoassay (LIA) (IBL, Hamburg, Germany) that had originally 
developed for analysis of cortisol concentration in saliva (cortisol saliva, IBL, Hamburg). This 
luminescent immunoassay is based on the competition principle: An unknown amount of 
antigen present in the sample competes with a fixed amount of enzyme-labeled antigen for 
binding to a limiting amount of plate-bound antibody. After incubation, the wells are washed 
to remove unbound labeled and unlabeled antigen. Then, luminescence substrate solution is 
added and luminescence is quantified in a luminometer, the measured luminescence intensity 
is inversely proportional to the amount of the antigen in the sample. Cortisol concentrations 
can thus be determined according to a standard curve. Since cortisol shows a strong diurnal 
regulation, all samples were obtained at similar times in the morning. Serum samples from 
healthy donors were used as reference healthy control and all measurements were performed 
in triplicate. Results were further validated using reference samples provided in the kit. 
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2.2.12 Isolation of bone marrow for adoptive transfer 
 
To investigate the effect of specific mutations in the immune system, hematopoietic stem-cell 
transfer has become a standard technique. To this aim, host hematopoietic cells are first killed 
by ionizing radiation, and then hematopoietic system is replaced by transfusion of donor bone 
marrow or purified hematopoietic stem cells. The resulting individuals are termed irradiation 
bone marrow chimeras. 
 
Bone marrow was flushed under sterile conditions from the medullary cavities of tibiae and 
femurs of CD45.1 (Ly5.1), GR
flox/flox 
and Lck-Cre GR
flox/flox
 mice, using RPMI1640 medium 
and a 21-gauge needle. (A T cell-specific knockout mutant of the GR was generated by a 
collaboration partner (Wüst et al., 2008) by introducing two loxP recombination sites around 
exon 3 of the GR (Nr3c1) and cross-breeding the GR
flox/flox
 mice with mice expressing a Cre 
transgene under the control of the proximal lck promoter (Lck-Cre). Due to activation of the 
Lck-promoter during T cell development, the resulting Lck-Cre GR
flox/flox
 mice possess ly 
GR-deficient T cells.) A single cell suspension was obtained by passing the whole bone 
marrow through a 70 µm cell strainer. Then, cells were washed and counted and CD90.2
- 
hematopoietic stem cells were isolated by magnetically-activated cell sorting (MACS) 
technology (Miltenyi). 
 
2.2.12.1 Isolation of the CD90.2
-
 hematopoietic stem cells by Magnetically-activated cell 
sorting (MACS) technology 
 
CD90 is a differentiation marker that is expressed on hematopoietic stem cells. Depending on 
the respective mouse strain, 2 different isoforms CD90.1 or CD90.2 can be expressed which 
can be used to trace adoptively transferred cells. In our setting, however, the two different 
isoforms of CD45 (Ly5.1) were used for tracing while CD90.2 represented a differentiations 
marker. For magnetic depletion of differentiated T cells, the CD90.2 (Thy1.2)
 +
 T cells are 
first magnetically labeled with CD90.2 MicroBeads.  Then, the cell suspension is loaded onto 
a MACS
® 
Column which is placed in the magnetic field of a MACS Separator. The 
magnetically labeled CD90.2
+
 cells are retained within the column. The unlabeled cells run 
through; this cell fraction is thus depleted of CD90.2
+ 
cells. The CD90.2
- 
hematopoietic stem 
cells are immature stem cells which can become tolerized upon adoptive transfer and thus do 
not mount a graft-versus-host reaction in the recipient mice. 
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2.2.12.2 Adoptive transfer of hematopoietic stem cells from Lck-Cre GR
flox/flox 
mice 
 
To investigate the immunomodulatory role of endogenous glucocorticoids in ovarian cancer 
in vivo, 129 S4/SvJae-C57BL/6JloxP-Stop-loxP-K-ras
G12D/+
Pten
loxP/loxP
-mice were irradiated 
with 11.5 gray divided into two doses (6 Gy and 5.5 Gy at an interval of 4 hours) to 
completely eradicate the recipient animals‟ hematopoietic stem cells. Within 24 hours, 
immunological reconstitution was performed by a single intra-venous injection of CD90.2
- 
hematopoietic stem cells obtained from bone marrow of Lck-Cre GR
loxP/loxP
 mice 
(Glucocorticoid receptor deficient T cells) and GR
loxP/loxP
 mice (reconstituted control). As 
additional control, mice were irradiated without bone marrow reconstitution. These animals 
died within 10-12 days from the effects of anemia. Since all used strains of mice 
endogenously express the CD45.2 allele, another control group was reconstituted with bone 
marrow from transgenic C57Bl/6-CD45.1 mice. This enabled the identification of adoptively 
transferred immune cells via an antibody raised against the CD45.1 allele. Thus, the 
reconstitution efficiency could be determined. Once the immune system of these irradiated 
mice had been reconstituted with glucocorticoid-insensitive T cells, ovarian carcinoma was 
subsequently induced by injection of the adenoviral Cre-recombinase into the ovarian bursa. 
The comparison between mice that had been reconstituted with glucocorticoid-responsive or 
glucocorticoid-resistant T cells, respectively, provides information on the role of endogenous 
glucocorticoids on T cells and on general anti-tumour immune responses in ovarian 
carcinoma. 
2.2.13 Statistics 
Experiments were performed at least three times with similar results. P values were 
determined by unpaired student t-test using Graphpad Prism 4. For flow cytometry data, SDs 
are indicated as calculated from the raw data by Summit software (BECKMAN COULTER).  
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3  Results 
3.1 Expression of 11-HSD1 in human ovarian cancer 
3.1.1 Expression patterns of 11-HSD1/2 in cryopreserved human ovarian cancer 
samples 
 
The expression of the 11-HSD1/2 was initially examined by immunohistochemistry on 
cryopreserved human tumour samples. Sections of liver (11-HSD1) and placenta (11-
HSD2) were stained as positive controls; healthy tissues were stained as negative controls. 
The results showed a high expression of the isoenzyme 11-HSD1 in 18/20 ovarian 
carcinomas (15 of the serous papillary, 5 of the endometroid subtype) but not in the 5 
investigated healthy ovaries. 
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Figure (15):  Overexpression of 11-HSD1 in human ovarian cancer tissues. Cryosections 
from liver (n = 2), healthy ovary (n = 5), cystadenomas (n=3) and ovarian cancers (n=20) 
were fixed in ice-cold acetone, rehydrated for 1 h with Tris-buffered saline, blocked with 10 
% normal goat serum and incubated overnight at 4°C  with  rabbit anti-human 11-HSD1 
antibody, followed by secondary HRP-labelled anti-rabbit–IgG. Stainings were developed 
using diaminobenzidine. (Pictures by courtesy of Dr. Claudia Heidbrink). 
 
 
 
 
 
 
 
 
 
 
71 
 
Expression of the 11-HSD2 was hardly detectable in the ovarian cancer samples. 
 
 
 
Figure (16): 11-HSD2 was hardly detected in human ovarian cancer tissues. 
Cryosections from human placenta (n = 2) and ovarian cancers (n = 10) were stained as in the 
previous Figure (15), using a rabbit anti-human 11-HSD2 antibody. (Pictures by courtesy of 
Dr. Claudia Heidbrink). 
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3.1.2 Expression of 11-HSD1 in fresh human ovarian tumour tissues and EpCAM-
positive ovarian cancer cell lines 
Total RNA was isolated from fresh human ovarian tumour tissue and ovarian cancer cell 
lines, transcribed into cDNA and the relative mRNA expression levels were determined by 
SybrGreen-based (semi-) quantitative real-time PCR (qRT)-PCR.  
 
 
 
Figure (17): Overexpression of 11-HSD1 in human ovarian cancer tissues.  RNA was 
isolated from ovarian cancer cell lines and primary tumour tissue and reverse-transcribed into 
cDNA. The transcriptional expression of 11-HSD1 was determined by SybrGreen-based 
quantitative PCR. Data were collected by Dr. Claudia Heidbrink and analyzed according to 
Ct-method. 
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3.1.3 Expression of 11-HSD1 in human OvCA tissues with CD14, CD68, CD85 and 
EpCAM 
 
The cellular attribution of 11-HSD1 expression in human ovarian cancer samples was 
examined by immunofluorescent double staining on cryosections from serous papillary, 
psammomatous serous and endometrioid ovarian carcinomas. This revealed a co-localization 
of 11-HSD1 with CD14, CD68, and CD85, but not with the tumour marker EpCAM. 
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Figure (18): Immunofluorescent double staining of 11-HSD1 with CD14, CD68, and 
CD85 in OvCA. Cryosections from 5 serous papillary, 5 psammomatous serous, 3 
endometrioid ovarian carcinomas   and 2 borderline tumours were stained with rabbit anti-
human 11-HSD1 antibody, antibodies against human CD14 (A), CD68 (B) and CD85(C). 
Immunofluorescent double staining was visualized by conjugated anti-Rabbit Alexa555 
antibody and conjugated anti-mouse Alexa488 antibody. (Pictures by courtesy of Dr. Claudia 
Heidbrink). 
 
 
 
 
Figure (19): Immunofluorescent double staining of 11-HSD1 with EpCAM in OvCA.  
Cryosections from 5 serous-papillary, 5 psammomatus-serous, 3 endometrioid ovarian 
carcinomas and 2 borderline tumours were stained with rabbit anti-human 11-HSD1 
antibody, conjugated mouse anti-human EpCAM-FITC antibody. 11-HSD1 staining was 
visualized by conjugated anti-Rabbit Alexa555 antibody. (Pictures by courtesy of Dr. Claudia 
Heidbrink). 
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3.2 Cortisol concentrations in serum, tumour exudates and ascites of OvCA patients 
 
Over-expression of 11-HSD1 in ovarian cancer was associated with elevated endogenous 
glucocorticoid levels. Cortisol levels in serum, tumour exudates and ascites of ovarian cancer 
patients were determined by luminescent immunoassays (LIA) which are based on 
competition between endogenous cortisol and the labelled glucocorticoid contained in the kit. 
The result showed elevated cortisol levels in serum, ascites and tissue exudates from ovarian 
cancer patients as compared to serum from healthy controls. It was strictly ensured that 
patients had not previously been treated with glucocorticoids of any kind for at least three 
months. 
 
 
 
 
Figure (20): High levels of cortisol in serum, tumour exudates and ascites of OvCA 
patients. Using  a  luminescence-based  immunoassay  which  was originally developed for 
analysis of cortisol in saliva,  the  morning  cortisol concentrations  were  determined  in  
serum, tumour exudates  and  ascites of ovarian  cancer  patients against a standard curve 
(correlation coefficient p = 0.998).  Serum samples from healthy control persons were 
collected at the same time and used as reference controls.  All measurements were performed 
in triplicate. (Data obtained from Dr. Claudia Heidbrink.) 
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3.3 Expression of GR in human OvCA-tissues and and ovarian cancer cell lines 
 
Protein lysates were isolated from normal ovaries, ovarian cancer (solid-papillary and 
endometrioid) and ovarian cancer cell lines. Glucocorticoid receptor (GR) expression on 
protein levels was determined by Western blot. GR was expressed in 17 out of 18 OvCA 
tissue samples and in 9/9 OvCA cell lines. The result revealed that cortisol may have direct 
effects on ovarian cancer cells. 
 
 
 
 
 
Figure (21): GR expression in normal ovaries, ovarian cancer and ovarian cancer cell 
lines. Expression of GR (95 kDa) was determined by Western blotting in samples from 
normal ovaries, ovarian cancer (sp = solid-papillary, e =endometrioid) and in ovarian cancer 
cell lines. Protein lysates were separated on a 10% SDS-polyacrylamide gel loaded with 20 
µg of total protein per lane, rabbit anti-human glucocorticoid receptor antibody was used, 
followed with HRP-conjugated secondary antibody. The same blot was stripped and 
neutralized for further detection of the endogenous loading control -actin. (Analysis 
performed by Dr. Claudia Heidbrink). 
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3.4 Viability and metabolic activity of the OvCA cell lines after treatment with cortisol 
Viability and metabolic activity of cortisol-treated OvCA cell lines were determined using the 
WST assay. For this purpose, the chromogenic tetrazolium salt WST was added to the cells 
and absorbance was measured 4 h later in an ELISA reader. The color reaction is based on the 
reduction of WST which can only occur in metabolically active (i.e. viable) cells. The result 
showed that treatment of OvCA cell lines with exogenous cortisol (up to 100 µM) had no 
effect on their proliferation and viability. 
 
 
Figure (22):  WST turnover of cortisol treated OvCA cell lines. Ovarian cancer cells were 
seeded in 96 well plates and treated the next day with different concentrations of cortisol. To 
determine the metabolic activity of treated and untreated cells, the tetrazolium salt WST-1 
was added after 46 h of incubation with cortisol. The colorimetric reaction of the tetrazolium 
salt WST was measured 4 h after addition to the cells in an ELISA reader at OD 450 nm 
(correction wavelength: 620 nm). Under these experimental conditions, the measured 
absorbance is proportional to the number of living cells. The intense brown color reaction is 
based on the reduction of WST which can only occur in metabolically active (= viable) cells. 
(Data kindly provided by Dr. Claudia Heidbrink). 
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3.5 Mouse ovarian carcinoma model 
3.5.1 Spontaneous mouse model for ovarian cancer 
 
A spontaneous mouse model for endometrioid ovarian cancer used to investigate the 
functional immunomodulatory role of endogenous GCs in ovarian cancer. For this model, an 
adenovirally encoded Cre-recombinase (AdCre) was injected into the ovarian bursa of 
129 S4/SvJae-C57BL/6JloxP-Stop-loxP-K-ras
G12D/+
Pten
loxP/loxP
 mice to induce the deletion of 
the PTEN tumour suppressor gene and the activation of the latent oncogenic K-ras
G12D
 
(Dinulescu et al., 2006). Due to the deletion of PTEN and the activation of K-ras, the mice 
developed ovarian cancer of the endometrioid subtype which became visible within 6-7 
weeks. Later, the mice also developed peritoneal metastases as evidenced by the formation of 
ascites in the abdominal cavity. 
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Figure (23):  Making a Mouse Model of Gynecologic Disease (Jeff Boyd, 2005; Dinulescu 
et al., 2006).  Dinulescu et al. genetically engineered mice to carry latent alleles of active 
mutant K-ras (left side) or active mutant K-ras and inactive Pten (right side). Injection of an 
adenoviral Cre recombinase construct into the ovarian bursa led to tissue-specific expression 
of active mutant K-ras, resulting in pelvic endometriosis, or tissue-specific expression of 
active mutant K-ras and inactivation of Pten, resulting in metastatic endometrioid ovarian 
carcinoma. 
 
3.5.2 Generation of cell lines from mouse ovarian tumour 
 
I managed to generate four mouse ovarian cancer cell lines (MOVCA -3, -4, -5 and -6) 
originate from our spontaneous mouse model for endometrioid ovarian cancer (Dinulescu et 
al., 2006) by digesting mouse ovarian cancer tissues via dispase and a single cell suspension 
was obtained by passing the digested mixture through a 70 µm cell strainer. Thereafter, cells 
were repeatedly passaged in vitro. Then, cell lines were obtained by using limiting dilution 
method in order to clone individual cells per well. All cell lines were EpCAM positive. 
Moreover, three of these cell lines are expressing K-ras and Pten whereas one cell line is 
having K-ras and lacking Pten. In future, these mouse ovarian cancer cell lines could help for 
further investigation of molecular and immune interactions in ovarian cancer development.  
A 
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Figure (24): Expression of Kras, Pten in mouse ovarian cancer cell lines.  RNA was 
isolated from murine ovarian cancer cell lines or Kras/Pten ovarian cancer tissue as positive 
control and Wt as negative control and reverse-transcribed into cDNA. Kras (A) and Pten (B) 
expression levels were determined using RT-PCR. GAPDH was amplified as loading control 
(C). 
 
 
                   
 
 
 
 
Figure (25): GR expression in normal ovaries, ovarian cancer and ovarian cancer cell 
lines. Expression of Pten (54 kDa) and EpCAM (34 kDa) were determined by Western 
blotting in samples from murine ovarian cancer cell lines and SK-OV-3 or OAW42 as 
positive controls. Protein lysates were separated on a 10% SDS-polyacrylamide gel loaded 
with 20 µg of total protein per lane, rabbit anti-mouse Pten antibody was used, followed with 
HRP-conjugated secondary antibody. For EpCAM biotin rat anti-mouse antibody was used, 
followed with followed by Streptavidin-HRP. The same blot was stripped and neutralized for 
further detection of the endogenous loading control -actin.  
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3.6 Expression of 11-HSD1 in murine ovarian cancer 
 
To check whether 11-HSD1 and 11-HSD2 expression levels in the inducible murine 
ovarian cancer model reflect those previously observed in the human disease, we performed 
immunohistochemical staining on cryopreserved mouse ovarian tumour material. Healthy 
ovarian tissues from non-induced littermates were stained as negative controls.  
 
 
Figure (26): Overexpression of 11-HSD1 in mouse ovarian cancer tissue. The 
129S4/SvJae-C57BL/6J loxP-Stop-loxP-K-ras
G12D
/Pten
loxP/loxP
 mice were sacrificed 8 weeks 
after intra-bursal injection of adenoviral Cre which leads to the induction of an endometrioid 
ovarian cancer. Tumours (middle and bottom) and contralateral normal ovaries (above) were 
frozen in liquid nitrogen. Sections of ovarian cancer tissues and normal ovaries tissues were 
stained with rabbit anti-mouse 11-HSD1 (left) and sheep anti-mouse 11-HSD2 (right). 
(Pictures by courtesy of Dr. Sebastian Häusler). 
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3.7 Adoptive transfer of hematopoietic stem cells from GR-deficient mice 
 
The intratumoral expression of 11-HSD1 in the inducible mouse model for ovarian cancer 
opened up the possibility to investigate whether glucocorticoid-insensitive immune cells 
could mount a superior immune response against the tumour. To this aim, bone marrow 
chimeras were created. Thus, recipient mice harboring the Pten
loxP/loxP
 and loxP-Stop-loxP-
kras
G12D
 alleles were first irradiated and then adoptively transferred with CD90.2
- 
hematopoietic stem cells isolated from the bone marrow of either Lck-Cre GR
loxP/loxP
mice (T 
cell specific glucocorticoid receptor knock-out mice) or GR
loxP/loxP
 mice. (Due to the absence 
of Cre-recombinase, these mice display similar GR expression levels as the wild-type 
controls.) Bone-marrow derived CD90.2
-
 hematopoietic stem cells from CD45.1 (Ly5.1) mice 
(n=2) served as additional control to monitor the reconstitution of the immune system with the 
adoptively transferred cells. All irradiated recipient mice were injected with 2x10
6 
CD90.2
-
 
cells into the tail vein with the exception of 2 mice that did not receive bone marrow transfer 
and thus died from anemia after 8-10 days. After the adoptively transferred cells had been 
allowed to engraft for 30 days, the mice that had received CD45.1 cells were sacrificed and 
immunological reconstitution was confirmed by FACS analysis of CD45.2 (host) and CD45.1 
(transferred) cells from the spleen. After reconstitution, ovarian cancer was induced by 
injection of the adenoviral Cre-recombinase into the ovarian bursa and tumour development 
was observed. The survival percentage of these mice was plotted in a Kaplan-Meyer curve. 
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Figure (27): Adoptive transfer of control and GR-deficient immune cells into 
129S4/SvJae-C57BL/6J loxP-Stop-loxP-K-ras
G12D
/Pten
loxP/loxP
 recipient mice followed by 
induction of ovarian cancer. A Kaplan-Meyer curve was plotted for recipient mice that had 
received Lck-Cre GR
oxP/loxP   
(n=5) or GR 
loxP/loxP 
control cells (n=7) before Cre-mediated 
induction of ovarian cancer. P value was determined by unpaired student t-test using 
Graphpad Prism 4. 
 
Contrary to our hypothesis, we observed that mice with glucocorticoid-insensitive T cells 
show an even shorter survival than their littermates with a normal (though adoptively 
transferred) immune system. This raised the question whether T cells that were no longer 
inhibited by endogenous glucocorticoids might assume a phenotype that promotes rather than 
inhibits tumour growth. Such properties have been described for regulatory T cells. We thus 
checked tumours from both groups for the presence of tumour-infiltrating immune cells with 
particular attention on Treg. 
 
 
 
86 
 
Figure (28): Expression of CD4
+ 
T cells in murine ovarian cancer tissues. Cryosections of 
ovarian cancer tissues from mice reconstituted with bone marrow obtained from Lck-Cre 
GR
loxP/loxP
 (n=1) or GR
loxP/loxP
 (n=1) control mice and healthy ovarian tissues (n=1) were fixed 
in ice-cold acetone, rehydrated for 1 h with Tris-buffered saline, blocked with 10 % normal 
goat serum and incubated overnight at 4 °C with rat anti-mouse CD4
+ 
antibody, followed by 
secondary HRP-labelled anti-rat–IgG. The stainings were developed with diaminobenzidine. 
 
3.8 Expression of FOXP3
+
 in murine ovarian tumour tissues 
 
The expression of the Treg master transcription factor FOXP3
+ 
was determined by 
immunohistochemistry on cryopreserved mice tumour samples. Sections of ovarian cancer 
tissues from mice reconstituted with bone marrow from Lck-Cre GR
loxP/loxP
 or GR
loxP/loxP
 
control mice were stained for FOXP3
+
; healthy ovarian tissues were stained as negative 
controls. The result showed that FOXP3
+ 
was highly expressed in the ovarian cancer from 
mice reconstituted with hematopoietic stem cells from Lck-Cre GR
loxP/loxP
 donor mice but not 
in mice reconstituted with GR 
loxP/loxP
 control cells or healthy ovarian tissues. Thus, it may by 
hypothesized that abrogation of GR signaling in T cells improves T cell infiltration into the 
tumour tissue. However, T cells that have entered the tumour microenvironment tend to 
assume a tolerogenic phenotype. Accordingly, inhibition of endogenous glucocorticoids can 
even have a negative overall effect unless further immunosuppressive mechanisms (e.g. 
conditioning of the tumour microenvironment by TGF-) are also addressed. 
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Figure (29): Expression of FOXP3
+
in murine ovarian cancer tissues. Cryosections of 
ovarian cancer tissues from mice reconstituted with bone marrow obtained from Lck-Cre 
GR
loxP/loxP
 (n=1) or GR
loxP/loxP
 (n=1) control mice and healthy ovarian tissues (n=1) were fixed 
in ice-cold acetone, rehydrated for 1 h with Tris-buffered saline, blocked with 10 % normal 
goat serum and incubated overnight at 4°C with mouse anti-mouse FOXP3
+ 
antibody, 
followed by secondary HRP-labelled anti-mouse–IgG. The stainings were developed with 
diaminobenzidine. 
 
3.9 Expression of DCIR2 in murine ovarian tumour tissues 
 
CD8
+
DEC-205/CD205
+ 
dendritic cells (DCs) may convert Foxp3
-
 precursors into Foxp3
+
 Treg 
in a TGF- independent manner. CD8-DCIR2+ DCs do, in contrast, promote the expansion of 
Foxp3
+
 Treg in the presence of TGF- (Yamazaki et al., 2008). Since these CD8
-
DCIR2
+
 
constitute the major fraction of inhibitory dendritic cells (DCs), we assessed expression of 
DCIR2 by immunohistochemistry on cryopreserved mice tumour samples. Sections of ovarian 
cancer tissue from mice reconstituted with bone marrow from Lck-Cre GR
loxP/loxP
 or 
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GR
loxP/loxP
 control mice were stained for DCIR2; healthy ovarian tissues were stained as 
negative controls. This revealed a greatly enhanced DCIR2 expression in ovarian cancer 
specimens from mice reconstituted with hematopoietic cells from Lck-Cre GR
loxP/loxP
donors, 
but not in mice reconstituted with control (GR
loxP/loxP
) bone marrow or healthy ovarian tissues. 
Considering that the only difference between mice reconstituted with Lck-Cre GR
loxP/loxP
 and 
mice reconstituted with GR
loxP/loxP
 cells is GR expression in T cells which then leads to 
different levels of T cell infiltration, it appears likely that changes in antigen-presenting cells 
occur in response to infiltrating T cells. Moreover, the high abundance of CD8
-
DCIR2
+
 DCs 
which can expand natural Foxp3
+
 Treg in a TGF- dependent manner may explain the high 
numbers of Foxp3
+
 T cells in this group and point towards a role for TGF-. 
 
 
Figure (30):  Expression of DCIR2 in mouse ovarian cancer tissues. Cryosections of 
ovarian cancer tissues from mice reconstituted with bone marrow obtained from Lck-Cre 
GR
loxP/loxP
 (n=1) or GR
loxP/loxP
 (n=1) control mice and healthy ovarian tissues (n=1) were fixed 
in ice-cold acetone, rehydrated for 1 h with Tris-buffered saline, blocked with 10 % normal 
goat serum and incubated overnight at 4 °C with biotin rat anti-mouse DCIR2 antibody, 
followed by Streptavidin-HRP. The stainings were developed using diaminobenzidine.  
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3.10 Expression of 11-HSD1 in murine ovarian tumour tissues from bone marrow 
chimeras 
 
Ovarian carcinomas grown in irradiated 129S4/SvJae-C57BL/6J loxP-Stop-loxP-K-
ras
G12D
/Pten
loxP/loxP
 mice that had been reconstituted with bone marrow stem cells from lck-
Cre GR
loxP/loxP
, GR
loxP/loxP
 and CD45.1 (Ly5.1) mice were explanted, RNA was extracted from 
the various tumours and from healthy ovaries of control mice, cDNA was prepared via reverse 
transcription and the expression of 11-HSD1 was determined by reverse transcriptase 
polymerase chain reaction.  
 
 
Figure (31): Expression of 11-HSD1 in mice ovarian cancer tissues.  RNA was isolated 
from murine ovarian cancer tissues of Lck-Cre GR
loxP/loxP
 (n=2) or GR
loxP/loxP
 (n=2) control 
mice or CD45.1 (n=2) control mice and healthy ovarian tissues (n=2) and reverse-transcribed 
into cDNA. 11-HSD1 expression levels were determined using RT-PCR for 35 cycles (A). 
GAPDH was amplified as loading control (B). 
3.11 Expression of 11-HSD1 and GR mRNA as analysed by qRT-PCR from fresh 
murine ovarian tumour tissues 
 
RNA was isolated from fresh murine ovarian tumour tissues (irradiated 129S4/SvJae-
C57BL/6J loxP-Stop-loxP-K-ras
G12D
/Pten
loxP/loxP
 mice that had been reconstituted with bone 
marrow stem cells from lck-Cre GR
loxP/loxP
 or GR
loxP/loxP
 mice) and from healthy ovaries. 
90 
 
cDNA was obtained by reverse transcription and the expression of 11-HSD1 and GR mRNA 
were determined by SybrGreen-based real-time quantitative (qRT)-PCR. 
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Figure (32): mRNA expression of 11-HSD1 and GR in murine ovarian cancer tissues.  
RNA was isolated from murine ovarian cancer tissues and healthy ovaries and reverse 
transcribed into cDNA. The expression of 11-HSD1 (n=2) (A) and GR (n=3) (B), mRNA 
were determined by SybrGreen-based quantitative PCR. The data were analyzed according to 
Ct-method. P values were determined by unpaired student t-test using Graphpad Prism 4. 
 
3.12 Expression of IL-1α, IL-1β, TNF-α and MMP-9 mRNA using qRT-PCR in fresh 
murine ovarian tumour tissues 
 
RNA was isolated from fresh murine ovarian tumour tissue (irradiated 129S4/SvJae-
C57BL/6J loxP-Stop-loxP-K-ras
G12D
/Pten
loxP/loxP
 mice that had been reconstituted with bone 
marrow stem cells from lck-Cre GR
loxP/loxP
 or GR
loxP/loxP
 mice) and healthy ovaries and 
reverse-transcribed into cDNA. Then, the relative expression levels of IL-1α, IL-1β, TNF-α 
and MMP-9 were determined by SybrGreen-based quantitative real-time (qRT)-PCR. This 
revealed higher levels of IL-1in the group with GR-responsive T cells (GRloxP/loxP) whereas 
mice harboring GR-deficient Lck Cre GR
loxP/loxP
 T cells displayed higher expression of the 
inflammatory markers IL-1and TNF- and of the TGF- inducible protease MMP-9. While 
this is in line with the anti-inflammatory effects mediated via the GR, it cannot be ruled out 
that GR-deficient T cells were not fully functional either. In this context, a recent publication 
(Mittelstadt et al., 2012) showed that Lck Cre GR
loxP/loxP
 were immunocompromised due to 
some defects occurring during positive selection in the thymus. 
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Figure (33): mRNA expression of IL-1α, IL-1β, TNF-α and MMP-9 in murine ovarian 
cancer tissues.  RNA was isolated from mouse ovarian cancer tissues and healthy ovaries and 
reverse-transcribed into cDNA. Expression levels of IL-1α (n=2) (A), IL-1β (n=3) (B), TNF-α 
(n=3) (C) and MMP-9 (n=2) (D), mRNA were determined by SybrGreen-based quantitative 
PCR. Data were analyzed according to Ct-Method. P values were determined by unpaired 
student t-test using Graphpad Prism 4. 
 
Taken together, these data show that endogenous glucocorticoids play an immunomodulatory 
role in ovarian cancer. When T cells are rendered resistant against the immunosuppressive 
effects of glucocorticoids, tumour infiltration by immune cells is significantly improved. 
However, as further immune-inhibitory mechanisms are at work in the tumour 
microenvironment, the infiltrating cortisol-resistant T cells cause some inflammation, but 
mostly assume a regulatory phenotype. Both phenomena may even promote tumour growth 
(as evidenced by shorter survival or mice that have been adoptively transferred with Lck-Cre 
GR
loxP/loxP
 cells). Thus, we had to conclude that inhibition of glucocorticoid receptor signaling 
would not be a promising strategy to improve tumour immune responses. Moreover, two 
contaminations with mouse parvovirus (MPV) led to a temporary, but long-lasting (18 
months) closure of the animal facility which prevented us from performing additional 
experiments in our mouse model. Instead, we directed our interest towards possible ways of 
enhancing the functionality of human immune cells (mainly NK cells, in this case) in the 
presence of glucocorticoids. 
 
3.13 Inhibition of NK cell degranulation by cortisol and TGF-
 
First, we confirmed the immunosuppressive effect of cortisol and TGF- by cell surface 
staining for the degranulation marker lysosomal-associated membrane protein-1 (LAMP-1) 
which is also known as CD107a. In cytotoxic immune cells, CD107a is normally found on the 
vesicular membrane surrounding the cytotoxic granule but not at the cell surface. Upon 
exocytosis of these granules, however, the vesicle membrane fuses with the cell membrane 
thereby leading to the sudden appearance of CD107a on the cell surface. Accordingly, 
degranulation can be assessed via surface staining for CD107a. To investigate the effect of the 
selected immunosuppressive factors, polyclonal NK cells were treated or not for 72 h with 
cortisol or TGF-β1 or both. Prior to the staining, the cells were activated with PMA and 
Ionomycin directly followed by addition of Golgi stop (monensin) to the mixture this stops 
the exocytosis and the acidification of endosomes. CD107a expression on the cell surface was 
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then analyzed by extracellular FACS staining. As expected, LAMP-1 was down-regulated by 
both Cortisol and TGF-β1 which also acted synergistically. 
 
 
 
 
 
 
Figure (34): Expression of CD107a on NK cells. Polyclonal NK cells were prepared from 
PBLs of healthy donor s and either left untreated or treated with 5 µM cortisol or 5ng/ml 
TGF-β1 or both for 72 h. Then, the cells were stimulated with PMA/Ionomycin followed by 
Golgi stop (1:1000, 6µg/ml) for 4 h. Surface expression of CD107a on CD3
-
CD56
+
, i.e. NK 
cells, was analyzed by flow cytometry (A). To obtain specific fluorescence intensity (SFI) 
values, the mean fluorescence values obtained with a PE-conjugated anti-CD107a antibody 
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were divided by the mean fluorescence values obtained with a PE-labeled isotype control 
antibody (B). A representative experiment (n=2) is shown. 
 
3.14 Activating receptors on NK cells and their response to cortisol and TGF-
 
In order to understand how NK cells might still be activated in the presence of endogenous 
glucocorticoids, we assessed the effects of cortisol on activating NK cell receptors. Since 
TGF- (which is abundant in the tumour microenvironment) is known to suppress expression 
of several of these receptors, TGF-1was included as control.  
 
3.14.1 Expression of NKG2D on NK cells 
 
NKG2D is an activating receptor expressed on NK cells, CD8 T cells and further cell types. 
Primary polyclonal NK cells were treated with cortisol or TGF-β1 or both (cortisol /TGF-β1) 
or left untreated as control. Expression of NKG2D on NK cells was analyzed by flow 
cytometry. The result indicated that NKG2D is downregulated by both cortisol and TGF-β1. 
Cortisol and TGF-β1 were further found to act synergistically in downregulating NKG2D. 
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Figure (35): Expression of NKG2D on NK cells. Polyclonal NK cells were prepared from 
PBLs of healthy donors and either left untreated or treated with 5 µM cortisol or 5ng/ml TGF-
β1 or both  for 72 h. NKG2D surface expression was analyzed on CD3-CD56+ cells (i.e. NK 
cells) by flow cytometry (A). To obtain specific fluorescence intensity (SFI) values, the mean 
fluorescence values obtained with a PE-conjugated anti-NKG2D antibody were divided by the 
mean fluorescence values obtained with a PE-labeled isotype control antibody (B). A 
representative experiment (n=5) is shown. P values were determined by unpaired student t-
test using Graphpad Prism 4. 
 
To explore potential effects of cortisol and TGF-β1 on NKG2D mRNA levels, polyclonal NK 
cells were treated for 6 h with cortisol or TGF-β1 or both or left untreated as control. RNA 
was isolated, reverse-transcribed and NKG2D mRNA expression was quantified by qRT-
PCR. Similar to the surface expression data this revealed a synergistic down-regulation of 
NKG2D by both cortisol and TGF-β1.  
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Figure (36): NKG2D mRNA expression in NK cells.  RNA was isolated from NK cells that 
had been left untreated or been treated for 6 h with 5 µM cortisol or 5 ng/ml TGF-β1 or both. 
After reverse transcription into cDNA, relative expression of NKG2D was analyzed by 
SybrGreen-based quantitative PCR using the following primers: 5´-
TCTCGACACAGCTGGGAGATG-3´ and 5´-GACATCTTTGCTTTTGCCATCGTG-3´ 
.18S rRNA was used as internal control. Data were analyzed according to Ct-method 
(n=3). P values were determined by unpaired student t-test using Graphpad Prism 4. 
 
3.14.2 Expression of natural cytotoxicity receptors on NK cells 
 
Natural cytotoxicity receptors (NCRs) include NKp46, NKp44 and NKp30. Polyclonal NK 
cells were again treated for 72 h with cortisol or TGF-β1 or both or left untreated as control. 
Expression levels for the different NCRs on NK cells were analyzed by flow cytometry. 
Surprisingly, this revealed that NKp46 is even up-regulated in response to cortisol, but down-
regulated with TGF-β1, always using the untreated control for comparison.  
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Figure (37): Expression of NKp46 on NK cells. Polyclonal NK cells were prepared from 
PBLs of healthy donors and either left untreated or treated with 5 µM cortisol or 5ng/ml TGF-
β1 or both for 72 h. The surface expression of NKp46 was analyzed on CD3-CD56+ NK cells 
(A) and specific fluorescence intensities (SFI values) were calculated for NKp46 (B). A 
representative experiment (n=4) is shown. P values were determined by unpaired student t-
test using Graphpad Prism 4. 
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mRNA data, in contrast, showed a slight downregulation of NKp46 mRNA with cortisol and 
a much more pronounced reduction in NKp46 mRNA levels in response to TGF-1. Still, the 
mRNA data support the finding that NKp46 expression remains largely intact after treatment 
with cortisol. 
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Figure (38): NKp46 mRNA expression in NK cells.  RNA was isolated from NK cells that 
had been treated for 6 h with 5 µM cortisol or 5ng/ml TGF-β1 or both. After reverse 
transcription into cDNA, expression of NKp46 was analyzed relative to an untreated control, 
using SybrGreen-based quantitative PCR with the following primers: 5´-
ACAACCATGCCTGGTCTTTC-3´and 5´-AAAAGGTAGCGTGCCCCAAGT-3´.18S rRNA 
was used as internal control. Data were analyzed according to Ct-method (n=3). P values 
were determined by unpaired student t-test using Graphpad Prism 4. 
 
For NKp44, the result showed that NKp44 is down-regulated in response to cortisol treatment 
whereas TGF-β1 has no effect on NKp44. 
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Figure (39): Expression of NKp44 on NK cells. Polyclonal NK cells were prepared from 
PBLs of healthy donors and either left untreated or treated with 5 µM cortisol or 5 ng/ml 
TGF-β1 or both  for 72 h. Surface expression of NKp44 on CD3-CD56+ NK cells was 
analyzed by flow cytometry (A) and specific fluorescence intensities (SFI values) were 
calculated (B). A representative experiment (n=3) is shown. P values were determined by 
unpaired student t-test using Graphpad Prism 4. 
On mRNA level, NKp44 expression was not detected in cortisol or TGF-1 treated NK cells, 
but was detected in the control. 
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NKp30, in contrast, was down-regulated by either cortisol or TGF-β1 with both shown a 
synergistic effect on protein and mRNA level. 
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Figure (40): Expression of NKp30 on NK cells. Polyclonal NK cells were prepared from 
PBLs of healthy donors and either left untreated or treated with 5 µM cortisol or 5 ng/ml 
TGF-β1 or both for 72 h. Surface expression of NKp30 on CD3-CD56+ NK cells was 
analyzed by flow cytometry (A) and SFI values were determined (B). A representative 
experiment (n=3) is shown. P values were determined by unpaired student t-test using 
Graphpad Prism 4. 
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Figure (41): NKp30 mRNA expression in NK cells.  RNA was isolated from NK cells that 
had been treated for 6 h with 5 µM cortisol or 5ng/ml TGF-β1 or both. After reverse 
transcription into cDNA, expression of NKp30 was analyzed relative to an untreated control, 
using SybrGreen-based quantitative PCR with the following primers: 5´-
TGTCCTGAGAAATGGGAAGG-3´and 5´-ACAGTGTTCAGGGACCCAAG-3´ .18S rRNA 
was used as internal control. Data were analyzed according to Ct-method (n=3). P values 
were determined by unpaired student t-test using Graphpad Prism 4. 
 
3.14.3 Expression of DNAM-1 on cortisol- or TGF--treated NK cells 
 
DNAX accessory molecule-1 (DNAM-1), also known as CD226, is an activating NK cell 
receptor that was found to mediate a major part of NK cell cytotoxicity against cancer cells 
including cell lines derived from ovarian carcinoma (Carlsten et al., 2009). Polyclonal NK 
cells were thus treated for 72 h with cortisol or TGF-β1 or both or left untreated as control. 
The expression of DNAM-1 on NK cells was analyzed by flow cytometry. The result 
indicated that cortisol does not affect DNAM-1 surface expression whereas TGF-β1 is able to 
(slightly) downregulate DNAM-1 on NK cells. 
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Figure (42): Expression of DNAM-1 on NK cells. Polyclonal NK cells were prepared from 
PBLs of healthy donors and either left untreated or treated with 5 µM cortisol or 5 ng/ml 
TGF-β1 or both for 72 h. Surface expression of DNAM-1 (CD226) on CD3-CD56+ NK cells 
was analyzed by flow cytometry (A) and SFI values were determined (B). A representative 
experiment (n=3) is shown. P values were determined by unpaired student t-test using 
Graphpad Prism 4. 
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On mRNA level, DNAM-1 expression was slightly up-regulated by either cortisol or TGF-.  
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Figure (43): DNAM-1 mRNA expression in NK cells.  RNA was isolated from NK cells 
that had been treated for 6 h with 5 µM cortisol or 5ng/ml TGF-β1 or both. After reverse 
transcription into cDNA, expression of DNAM-1 mRNA was analyzed relative to an 
untreated control, using SybrGreen-based quantitative PCR with the following primers: 5´-
GCAGTGACCAAGAGGGTGTT-3´ and 5´-CTGCTCGCTCTAACGCTTCT-3´.18S rRNA 
was used as internal control. Data were analyzed according to Ct-method (n=3). P values 
were determined by unpaired student t-test using Graphpad Prism 4. 
 
3.14.4 Expression of 2B4 on NK cells 
 
2B4 (CD244) is an activating NK cell receptor which mainly functions as co-receptor rather 
than as true receptor. To explore a potential regulation of 2B4 by cortisol or TGF-β1, 
polyclonal NK cells were again treated for 72 h with cortisol or TGF-β1 or both or left 
untreated as control. The expression of 2B4 on NK cells was analyzed by flow cytometry.  
The result showed that 2B4 expression remains basically unaltered in the presence of cortisol 
or TGF-β1. 
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Figure (44): Expression of 2B4 on NK cells. Polyclonal NK cells were prepared from PBLs 
of healthy donors and either left untreated or treated with 5 µM cortisol or 5 ng/ml TGF-β1 or 
both for 72 h. Surface expression of 2B4 (CD244) on CD3
-
CD56
+
 NK cells was analyzed by 
flow cytometry (A) and SFI values were determined (B). A representative experiment (n=3) is 
shown. P values were determined by unpaired student t-test using Graphpad Prism 4. 
 
On mRNA level, however, 2B4 was hardly affected by cortisol and slightly up-regulated by 
TGF-.   
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Figure (45): 2B4 (CD244) mRNA expression in NK cells.  RNA was isolated from NK cells 
that had been treated for 6 h with 5 µM cortisol or 5ng/ml TGF-β1 or both. After reverse 
transcription into cDNA, expression of 2B4 mRNA was analyzed relative to an untreated 
control, using SybrGreen-based quantitative PCR with the following primers: 5´-
ACAAAAGGCCACATTCCAAG-3´ and 5´-AACCCAGAGAGGGGAGAAAA-3´ .18S 
rRNA was used as internal control. Data were analyzed according to Ct-method (n=3). P 
values were determined by unpaired student t-test using Graphpad Prism 4. 
 
3.14.5 Expression of CD2 on NK cells 
 
The last factor investigated on cortisol- or TGF-β1 -treated NK cells was the co-stimulatory 
molecule. Polyclonal NK cells were again treated for 72 h with cortisol or TGF-β1 or both or 
left untreated as control. Expression of CD2 on NK cells was analyzed by flow cytometry. 
The result indicated that CD2 is down-regulated with Cortisol or TGF-β1.  
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Figure (46): Expression of CD2 on NK cells. Polyclonal NK cells were prepared from PBLs 
of healthy donors and either left untreated or treated with 5 µM cortisol or 5 ng/ml TGF-β1 or 
both for 72 h. Surface expression of CD2 on CD3
-
CD56
+
 NK cells was analyzed by flow 
cytometry (A) and SFI values were determined (B). A representative experiment (n=3) is 
shown. P values were determined by unpaired student t-test using Graphpad Prism 4. 
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On mRNA level, downregulation of CD2 could be observed with Cortisol and hardly affected 
by TGF-with both factors acting in synergy.   
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Figure (47): CD2 mRNA expression in NK cells.  RNA was isolated from NK cells that had 
been treated for 6 h with 5 µM cortisol or 5ng/ml TGF-β1 or both. After reverse transcription 
into cDNA, expression of 2B4 mRNA was analyzed relative to an untreated control, using 
SybrGreen-based quantitative PCR with the following primers: 5´-
CCAGCCTGAGTGCAAAATTCA-3´and 5´-GACAGGCTCGACACTGGATTC-3´ .18S 
rRNA was used as internal control. Data were analyzed according to Ct-method (n=3). P 
values were determined by unpaired student t-test using Graphpad Prism 4. 
 
A brief summary showing how the different NK cell receptors are affected by cortisol and/or 
 is given in the table below. 
 
downregulation at the cell 
surface 
downregulation on mRNA level residual surface expression 
 cortisol TGF-1 synergy cortisol TGF-1 synergy cortisol TGF-1 synergy 
NKG2D ++ +++ + + + + + (+) - 
NKp30 + ++ ++ ++ ++ + ++ + (+) 
NKp44 ++ + -    + +++ + 
NKp46 - - - + + + +++ ++ +++ 
CD226 - + + - - - +++ ++ ++ 
2B4 - - - - - - +++ +++ +++ 
CD2 - - - + - + ++ ++ ++ 
 
Table (12): Summary on the observed effects of cortisol and/or TGF-1 on different 
activating NK cell receptors. Synergy was rated as positive when there was at least an 
additive effect. 
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3.15 Restimulation experiment on NK cells that had been treated with cortisol or TGF-
  
 
As shown in the first part of this thesis, cortisol levels are greatly elevated in ovarian cancer. 
This is most likely due to an increased expression of the enzyme 11-HSD1 on myeloid cells. 
11-HSD1 is known to regulate local glucocorticoid levels by conversion of biologically 
inactive cortisone into active cortisol. In a mouse model of ovarian cancer, however, adoptive 
transfer of glucocorticoid-insensitive T cells from Lck-Cre GR
loxP/loxP
 mice improved 
intratumoral T cell infiltration but worsened the outcome which may be related to an induced 
Treg phenotype that was observed in most T cells in the tumour microenvironment. 
Accordingly, we tried to devise a strategy for activating natural killer cells in the presence of 
immunosuppressants like cortisol or TGF-1. In the ideal case, NK cell activation could 
modulate the tumour microenvironment and make it more favorable for subsequent T cell 
responses.  
 
In this context, we found that the activating NK cell receptor NKp46 was not only resistant 
towards cortisol or TGF-1; it even displayed an enhanced surface expression upon treatment 
of NK cells with cortisol.  This raises the question whether NKp46 signalling could still be 
activated in NK cells even in the presence of glucocorticoids and whether this could restore 
the killing capacity of NK cells against tumour cells. This was tested by a restimulation 
experiment during which cortisol- or TGF-1-treated NK cells were activated either with 
agonistic NKp46 and CD2 antibodies (that were coupled to magnetic beads). As control for a 
cortisol- and TGF-1-sensitive pathway, plate-bound antibodies against NKG2D and 2B4 
were used. This revealed that beads loaded with NKp46 and CD2 antibodies could largely 
restore the killing capacity of cortisol-treated NK cells against K562 tumour cell targets. In 
contrast, no rescue was achieved in TGF- treated NK cells. In line with the strong down-
regulation of NKG2D in response to either cortisol or TGF-1, restimulation with plate-bound 
antibodies against NKG2D and 2B4 was altogether less effective even though a slight 
increase in killing capacity was achieved here for TGF-1 treated cells. NK cells treated with 
both TGF-1 and cortisol were refractory to either stimulation. Thus, we conclude that NK 
cells can still be activated in the presence of immunosuppressive cytokines. However, 
restimulation has to occur via a pathway that is not fully incapacitated by the respective 
immunosuppressive factors and is thus highly context-dependent. This may become extremely 
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difficult when several immune-inhibitory factors are simultaneously present (which, 
unfortunately, is the case in the tumour microenvironment). Accordingly, relief of 
immunosuppression may become an important addition to current immunotherapeutic 
regimens. 
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Figure (48): Restimulation experiment with NK cells that had been pretreated with 
cortisol or TGF-. On day 8 of their preparation, polyclonal NK cells were either left 
untreated or treated for 72 h with 5µM cortisol or 5ng/ml TGF-β1 or both. Afterwards, NK 
cells were co-cultured for further 48 h with MACSiBeads loaded with NKp46 and CD2 
antibodies or on plates that had been coated with anti-NKG2D and anti-2B4 antibodies or 
without further stimulation as control. NK cells were then added in triplicates at the indicated 
E(ffector): T(arget) ratio to luciferase-transfected K562 (K562-fluc) target cells (A: E:T ratio 
10:1, B: E:T ratio 5:1). Luciferase activity was measured after 72 h. A representative 
experiment (n=3) is shown.P values were determined by unpaired student t-test using 
Graphpad Prism 4. 
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4  Discussion 
 
Cancer immunotherapy has long been considered as an interesting concept for tumour 
treatment. For ovarian cancer there is clear evidence that immunological parameters are 
crucial for the clinical outcome: While infiltration of a tumour with cytotoxic T cells is a good 
prognostic sign (Zhang et al., 2003), an abundance of regulatory T cells correlates with poor 
survival (Curiel et al., 2004). This suggests that the bolstering of anti-tumour immune 
responses (Mantia-Smaldone et al., 2012) could provide a clinically meaningful benefit. 
Nevertheless, an attempted immunotherapy with adoptive transfer of genetically engineered T 
cells failed for ovarian cancer patients since the infused T cells neither infiltrated the tumour 
nor persisted in vivo (Kershaw et al., 2006). Likewise, antibody-mediated immunotherapy 
which has been very successful for other malignancies (Slamon et al., 2001; Weiner et al., 
2010) has been ineffective in ovarian cancer yet (Berek et al., 2009). Some clinically 
meaningful responses were at least achieved in a trial that aims at inducing immunity against 
the tumour antigen NY-ESO1 (Odunsi et al., 2012). Multi-peptide vaccination against a set of 
8-20 individually determined tumour antigens was found to be highly beneficial for renal cell 
carcinoma (Walter et al., 2012) and colorectal cancer (poster presented at ASCO 2012). This 
approach is currently being tested on a first ovarian cancer patient in our clinics (ongoing 
experimental treatment). Thus, some progress is being made with regard to the optimal mode 
of activating the immune system against ovarian cancer. 
 
Part of the problem, however, seems to be that ovarian cancer deploys multiple mechanisms 
to suppress immunity in the tumour microenvironment (Curiel et al., 2003;   Hemminki et al., 
2003;  Kryczek  et al., 2006;  Qian  et al., 2009;  Yigit et al., 2010;   Krempski et al., 2011). 
Accordingly, a better understanding of immunosuppression in the tumour microenvironment 
will be needed to develop more effective immunotherapies. In this context, promising animal 
data were obtained by targeting of tumour-associated macrophages (Galmbacher et al., 2010). 
Attempts to overcome negative regulation of immune responses on humans have also been 
positively evaluated in cancer patients. The antibody-mediated blockade of CTL-A4 on 
lymphocytes was found to be effective enough in melanoma patients to allow the approval of 
the respective antibody ipilimumab (Robert et al., 2011) in spite of considerable treatment-
related autoimmunity. With this same antibody, promising early clinical data were also 
obtained for ovarian cancer patients (Hodi et al., 2008). A slightly more tumour-specific 
approach would be the targeting of interactions between PD-1 on immune cells and PD-L1 on 
114 
 
tumour or accessory cells. Again, clinical data obtained on other diseases look promising 
(Topalian et al., 2012; Brahmer et al., 2012). Thus, the field of cancer immunotherapy seems 
to be rapidly evolving and the concept that immunosuppressive signals must be overcome in 
order to achieve the desired response is getting recognized. 
 
In this context, we have investigated 11β-HSD1 as a potential mediator of immune escape in 
ovarian cancer. 
 
11β-HSD1 is an oxido-reductase that is essential for the conversion of biologically inactive 
cortisone into active cortisol. Together with its counterpart 11β-HSD2 (which in vivo 
catalyzes the opposite reaction) 11β-HSD1 regulates the local bioavailability of cortisol. In 
ovarian surface epithelial cells, 11β-HSD1 induces a local anti-inflammatory environment in 
response to the ovulation-inducing increase in luteinizing hormone (“LH surge”) (Yong et al., 
2002; Rae et al.  2004). Since ovulation causes massive tissue damage which triggers the 
production of pro-inflammatory cytokines, induction of 11β-HSD1 and the resulting increase 
in local cortisol levels limit inflammatory responses in the ovarian surface epithelium.  
Importantly, there is epidemiological evidence that inflammation and the ovulation-associated 
injury-repair processes contribute to the development of ovarian cancer (Yong et al., 2002; 
Modan et al., 2001). Accordingly, there was a clear biological rationale for investigating a 
potential expression of the anti-inflammatory enzyme 11β-HSD1 in ovarian cancer tissues. In 
fact, immunohistochemical stainings revealed of 11β-HSD1 expression in 20/20 tumours with 
expression levels mostly exceeding that of human liver (used as positive control). Healthy 
tissues, in contrast, showed low or undetectable amounts of 11β-HSD1. 11-HSD2, on the 
other hand, was hardly detectable in human ovarian cancer tissues whereas clear stainings 
were obtained with tissue sections from placenta (used as positive control). Thus, the 
equilibrium between the two enzymes that catalyze either the activation or the inactivation of 
cortisol was clearly on the side of the anti-inflammatory enzyme 11β-HSD1. 
 
Interstingly, we found the highest 11β-HSD1 mRNA and protein expression in primary 
human ovarian cancer tissues, but not in cell lines or purified EpCAM-positive tumour cells 
from patient material. We thus performed immunofluorescent double stainings on primary 
human ovarian cancer tissues (serous-papillary, psammomatus -serous, endometrioid ovarian 
carcinomas and borderline tumours). These revealed a co-localization of 11β-HSD1 with 
markers expressed by tumour-infiltrating myeloid-derived suppressor cells (MDSC) or 
115 
 
tumour-associated macrophages (TAM) (CD14, CD68, and CD85) but not with the tumour 
cell marker EpCAM. Similarly high levels of 11β-HSD1 were detected in macrophages and 
dendritic cells (Thieringer et al., 2001; Zhang et al., 2005; Freeman et al., 2005). Thus, MDSC 
or TAMs are the cell types that are most likely responsible for conversion of biologically 
inactive cortisone into active cortisol in ovarian cancer. Functionally, this would represent a 
new mechanism of immunosuppression in the tumour microenvironment.  
 
We found that over-expression of 11-HSD1 in ovarian cancer correlated with elevated 
cortisol levels in serum, ascites and tissue exudates from ovarian cancer patients as compared 
to healthy controls (serum) or patients with primary peritoneal carcinoma (ascites). This is in 
line with some other studies in which high levels of cortisol were detected in blood, saliva and 
ascites from ovarian cancer patients (Touitou et al., 1996; Lutgendorf et al., 2008; Weinrib et 
al., 2010). We thus hypothesized that local activation of endogenous GC could impair anti-
tumour immune responses and thereby prevent a successful immunotherapy. Described 
effects of GC on the actual tumour cells, in contrast, seem to suppress rather than promote 
tumour growth. 
 
Nevertheless, we also explored effects of cortisol on ovarian cancer cells. On protein level, we 
found GR to be highly expressed in primary human ovarian cancer tissues, as well as in 
ovarian cancer cell lines. Accordingly, cortisol binding could have a direct effect on ovarian 
cancer cells. In vitro tests, however, did not show any effect of GC on tumour cell 
proliferation or viability. 
 
As human testing is limited, we then decided to address the immunomodulatory role of 
endogenous GC in in an inducible mouse model for ovarian cancer. Tumours grown in 
PTEN
loxP/loxP
; loxP-Stop-loxP-kras
G12D
 mice (Dinulescu et al., 2006) display a 
histomorphology and a metastatic pattern that closely resemble human ovarian cancer of the 
endometrioid subtype. In addition, the 11-HSD1 expression pattern corresponds to that 
found in the human disease. 
 
To determine the effect of GC on the spontaneous immune response in this tumour model,  
PTEN
loxP/loxP
; loxP-Stop-loxP-kras
G12D
 mice were adoptively transferred with CD90.2
- 
hematopoietic stem cells isolated from bone marrow of either Lck-Cre GR
loxP/loxP 
mice (T-cell 
GR-deficient mice) or GR
loxP/loxP
 mice (reconstituted control). CD45.1 (Ly5.1) expressing 
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donor mice were used as additional controls to assess successful immunological 
reconstitution. Once the immune systems of the reconstituted mice had been restored, tumour 
development was initiated by injection of adenoviral Cre-recombinase into the ovarian bursa 
and the tumours were allowed to grow until the animals developed symptoms and had to be 
sacrificed. Surprisingly, this showed a shorter survival of those mice that had been 
reconstituted with GC-insensitive T cells. Immunohistochemical investigation of the 
explanted tumours nevertheless revealed that the T cell-specific GR knock-out had enabled 
improved intratumoral infiltration with T cells and DCs as compared to control mice.  In GR-
deficient mice, however, the majority of infiltrating T cells displayed a Foxp3
+
 (regulatory) 
phenotype which might explain the poor survival of these mice. Along the same line, ex vivo 
studies observed that recruitment of regulatory T cells in ovarian carcinoma fosters immune 
privilege, poor prognosis and predicts reduced survival (Curiel et al., 2004; Wolf et al., 2005). 
Furthermore, plasmacytoid dendritic cells infiltrating ovarian cancer constitute an 
independent prognostic factor associated with early relapse (Labidi-Galy et al., 2012). 
Moreover, while the mice with a T-cell specific GR-deficiency showed increased autoimmune 
response in antigen-induced arthritis (Baschant et al., 2011), a very recent report describes 
that thymocyte responsiveness to endogenous GC is required for immunological fitness and 
robust adaptive immune responses. According to this source, thymocyte responsiveness to GC 
signaling promotes the selection of T cells that have sufficient affinity for self, whereas 
otherwise (in lck-Cre GR
loxP/loxP
-mice) an immunocompromised state might occur (Mittelstadt 
et al., 2012). Thus, impaired functionality of T cells or differentiation into Treg or both may 
have contributed to the unexpected outcome. 
 
To better understand the in vivo interactions between tumours and immune cells in these mice, 
messenger RNA (mRNA) was extracted from explanted tumours and analyzed for various 
pro-inflammatory and angiogenic markers. 11-HSD1, GR, IL-1β, TNF-α and MMP-9 
mRNA are highly expressed in OvCA from mice that had been reconstituted with Lck-Cre 
GR
loxP/loxP
 hematopoietic cells as compared to tumours from mice that had received GR
loxP/loxP  
cells and healthy ovaries from control mice , whereas only IL-1α,) mRNA showed the higher 
expression levels in tumours from mice with GC-sensitive lymphocytes. Healthy ovaries from 
control mice were again used as controls. These findings are in line with several studies which 
show that high expression of matrix metalloproteinases (MMP), key proteins required for 
tumour cell penetration of the extracellular matrix, promote overall tumour progression (Sood 
et al., 2006). Also, it appears likely that the high expression of 11-HSD1 in OvCA tissue is a 
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response to the abundant pro-inflammatory cytokines like IL-1α (Yong et al., 2002; Chapman 
et al., 2006), IL-1β (Escher et al., 1997; (Cai et al., 2001; Tomlinson et al., 2001; Li et al., 
2006; Chapman et al., 2006) and TNFα (Escher et al., 1997; Thieringer et al., 2001; Cai et al., 
2001; Tomlinson et al., 2001; Chapman et al., 2006). 
 
This experiment showed that the use of T cells that had been rendered insensitive to GCs 
could improve immune cell infiltration into the tumour microenvironment and thus overcome 
a major obstacle in cancer immunotherapy (Rosenberg, 2008). Vice versa, local activation of 
cortisol could be a further “road signs” that keep T cells out of the tumour microenvironment 
in ovarian cancer (Bagnato et al., 2005; Buckanovich et al., 2008; Schaer et al., 2011; Molon 
et al., 2011). Nevertheless, while this would normally be a desirable outcome (Fridman et al., 
2012), it appears that tumour-infiltrating T cells were rapidly tolerized (Bai et al., 2008) and 
thus acted in favor of the tumour rather than of the host. Accordingly, inhibition of GC 
signaling would have to be combined with vaccination or with antagonisation of further 
tolerogenic mechanisms in the tumour microenvironment. Unfortunately, however, a virus 
infection in the animal facility precluded further experiments in this direction.  
 
We thus decided to explore possibilities for initiating an anti-tumour immune response in the 
presence of glucocorticoids and TGF- which is also known to be abundant in the tumour 
microenvironment. GCs and TGF-β mutually contribute to the limitation and/or termination 
of inflammatory processes and are both involved in the regulation of cell growth, 
development and differentiation (Periyasamy and Sánchez, 2002; Peltier et al., 2003). 
Moreover, GCs and TGF-β modulate each other‟s activities (Periyasamy and Sánchez, 2002; 
Peltier et al., 2003). High levels of TGF-β have been detected in many tumours including 
ovarian cancer (Hirte & Clark 1991; Zeimet et al., 1998; Nash et al., 1999; Abendstein et al., 
2000; Santin et al., 2001). Among all cytokines, TGF-β possesses the strongest immune-
inhibitory properties. Nevertheless, its effect on immune cells is sometimes reversible (Wilson 
et al., 2011). High levels of cortisol have already been demonstrated in this thesis and were 
also detected by others in ovarian cancer ascitic fluid (Touitou et al., 1996; Lutgendorf et al., 
2008; Weinrib et al., 2010) and GCs exert anti-inflammatory and immune suppressive effects 
on immune cells (Sternberg, 2006).  In addition, glucocorticoids are often administered as a 
co-treatment with chemotherapy to reduce chemotherapy-related side effects (Runnebaum and 
Brüning, 2005; Zhang et al., 2006; Sui et al., 2006; Melhem et al., 2009; Chen et al., 2010). 
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Thus, both GCs and TGF-β likely contribute to immunosuppresion in ovarian cancer patients 
and both must be overcome in order to prevent immune escape. 
 
In this context, we placed a special focus on natural killer (NK) cells. NK cells constitute a 
vital part of the innate immune system and play a major role in the rapid immune responses 
against tumour cells and virus-infected cells (Kiessling et al., 1975; Herberman et al., 1975; 
Riccardi et al., 1980; Ljunggren and Karre, 1985; Natuk and Welsh 1987; Salazar-Mather et 
al., 1998; Biron et al., 1999; Janeway, 5th Edition, 2005; Lodoen and Lanier; 2006). 
Moreover, NK cells have been reported to play a central role in controlling tumour promotion, 
growth and metastasis in rodents and humans (Smyth et al., 2002) via release of immune-
stimulatory cytokines and cytolytic granules (Smyth et al., 2002). NK cells may be able to 
deliver the “spark” to initiate a more potent immune response involving further cell types 
(Kelly et al., 2002). Accordingly, there is a strong rationale for inducing NK cell responses 
against tumours. We thus investigated whether specific signaling pathways in NK cells could 
still be activated in the presence of GC and/or TGF-. To understand the influence of these 
factors on NK cell activation a careful investigation of the various activating NK cell 
receptors, including NKp30, NKp44, NKp46, DNAM-1, 2B4, CD2 and NKG2D, was carried 
out. 
 
Flow cytometeric analysis revealed that cortisol decreases the expression of NKp30, NKp44, 
CD2 and NKG2D on NK cells while upregulating NKp46.  Cortisol seems to have no effect 
on DNAM-1 or 2B4 expression. Similarly to cortisol, TGF-β1 decreases NKp30, CD2 and 
NKG2D expression levels on NK cells, but TGF-β1 can also downregulate DNAM-1. 
Interestingly, TGF-β1 does not affect expression of NKp46, NKp44, or 2B4. Cortisol and 
TGF-β1 act synergistically to further downregulate NKp30 and NKG2D receptors on NK 
cells. On mRNA level, the data revealed that cortisol decreases the expression of NKp30, 
CD2 and NKG2D on NK cells whereas only a slight down-regulation of NKp46 was 
observed. Also, Cortisol has no effect on DNAM-1and 2B4 mRNA expression, while NKp44 
was not detected in cortisol-treated NK cells. Likewise, TGF-β1 decreases the expression of 
NKp30 and NKG2D, but has no effect on CD2, DNAM-1 and 2B4, whereas NKp46 was only 
slightly down-regulated. NKp44 was not detected in TGF-β1-treated NK cells. Cortisol and 
TGF-β1 were further found to act synergistically in downregulating NKG2D, NKp30 and 
CD2. 
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Several studies provided evidence that methylprednisolone treatment, which is commonly 
applied to patients suffering from inflammatory conditions, generally reduces the surface 
density of the main activating receptors involved in NK cytotoxic function, including NKp30, 
NKp44 and NKG2D.  NKp46 expression on freshly isolated NK cells remained, in contrast, 
unaltered (Vitale et al., 2004; Chiossone et al., 2007). Another study reported that cortisol 
inhibited the surface expression of natural cytotoxicity receptors NKp46 and NKp30 on NK 
cells which correlated with a strongly reduced cytolytic activity of NK cells (Mavoungou et 
al., 2005). A similar phenomenon had been previously reported for TGF-β1 which strongly 
downregulates the expression of NKp30, NKG2D, DNAM-1 and 2B4 but not NKp46, leading 
to an impairment of NK cell effector functions (Castriconi et al., 2003; Friese et al., 2004; 
Robson et al., 2009; Carlsten et al., 2009; Wilson et al., 2011; Sun et al., 2012).  
 
In the present study, the down-regulation of activating NK cell receptors in response to 
treatment with cortisol, TGF-β1 or both resulted in a highly significant reduction of NK 
cytolytic activity against K562 cells. Likewise, CD107a expression which is a degranulation 
marker for the cytolytic activity of activated NK cells (Peters et al., 1991; Fukuda, 1991; Alter 
et al., 2004) was down-regulated upon treatment with either cortisol or TGF-β1 and was 
further downregulated upon treatment with both.  In a similar vein, other groups (Nair et al., 
1984; Callewaert et al., 1991; Zhou et al., 1997; Vitale et al., 2004; Mavoungou et al., 2005) 
have reported that impairment of expression of NK-triggering receptors leads to reduced 
cytotoxicity against different tumour targets. Also the reduction of CD107a surface levels on 
TGF-1- (Kopp et al., 2009; Wilson et al., 2011) or glucocorticoid-treated (Elftman et al., 
2010) cytotoxic effector cells was in accordance with the previous literature. 
 
A novel finding, however, was that surface expression of the activating NK cell receptor 
NKp46 can even by induced by cortisol treatment. Accordingly, we wondered whether 
NKp46 might keep up a certain NK cell functions even in individuals with high cortisol levels 
like ovarian cancer patients. Consequently, we investigated whether NK cells could be 
activated even in the presence of GCs via stimulation of NKp46. As a read-out, NK cell 
activity was assessed against K562 tumour cell targets. In line with this hypothesis, 
restimulation experiments with NK cell activation beads loaded with agonistic antibodies 
against NKp46 and CD2 revealed that the lytic activity of cortisol-treated NK cells could 
partially be restored. No rescue, however, was possible when via the triggering of NKG2D 
and 2B4 or when the cells had previously been exposed to TGF-β1. 
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Taken together, we have shown that endogenous glucocorticoids are abundant in ovarian 
cancer which is likely related to a high expression of the oxido-reductase 11-HSD1 on 
myeloid cells since this enzyme converts cortisone into biologically active cortisol. In an 
inducible mouse model for ovarian cancer, adoptive transfer of glucocorticoid-insensitive 
hematopoietic cells from Lck-Cre GR
loxP/loxP
 mice improved intratumoral T cell infiltration. 
Unfortunately, however, intratumoral T cells displayed a regulatory T cell phenotype which 
correlated with shortened survival. Still, synergy with therapies that rely on good intratumoral 
infiltration of highly activated T cells appears likely. In addition, immunomodulatory 
treatments that aim at a reduction of tumour-derived cortisol could benefit from the targeting 
of further tolerogenic factors in the tumour microenvironment (e.g. TGF-). Ideally, the 
infiltrating T cells could then retain an effector phenotype and exert an anti-tumour effect.  
 
In the second parrt of this thesis, in vitro experiments on primary human natural killer cells 
showed that both TGF-1 and glucocorticoids strongly inhibit the majority of immune-
activating pathways in these cells. NKp46, in contrast, gets even induced by glucocorticoids 
which suggest that this receptor serves to maintain a residual immune function in the presence 
of cortisol which could possibly be exploited for immunotherapy.  
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6 List of Abbreviations and Acronyms 
 
°C Celsius 
µg microgram 
µl microlitre  
µM  micromolar 
11β-HSD1 11-beta hydroxysteroid   dehydrogenase 1 
11β-HSD2 11-beta hydroxysteroid dehydrogenase 2 
2B4 natural killer cell receptor 2B4 
aa amino acid 
ACD-A sodium citrate solution 
ADCC antibody-dependent cellular cytotoxicity 
AdCre adenovirus encoded Cre-recombinase 
AICL activation-induced C-type lectin  
AP-1 activator protein 1 
APS ammonium persulfate 
BAT3 nuclear factor HLA-B associated transcript 3 
bp base pair 
BSA bovines serum albumin 
CA-125 cancer antigen 125 or carbohydrate antigen 125 
CBG corticosteroid binding globulin 
CD cluster of differentiation 
cDNA complementary DNA 
cIAP2 cellular inhibitor of apoptosis 2 
cm
2
 square centimeters 
CMV cytomegalovirus 
CO 2 carbon dioxide 
COX-2 cyclo-oxygenase-2 
CT cycle threshold 
CTLs cytotoxic T cells 
DAB diaminobenzidine 
DCs dendritic cells 
dd H2O double-distilled water 
DHEA dehydroepiandrosterone 
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DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
DNAM-1 DNAX accessory molecule-1 
dNTPs deoxynucleotide triphosphates 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EOC epithelial Ovarian Cancer 
EpCAM epithelial cell adhesion molecule 
EtOH ethanol 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FLuc firefly luciferase 
Foxp3
+
 Forkhead box P3   
GCs glucocorticoids 
gDNA genomic DNA 
GM-CSF granulocyte–macrophage colony-stimulating factor 
GR glucocorticoid receptor 
GRE glucocorticoid response element 
Gy Gray 
h hour 
H60a histocompatibility 60a 
HLA human leukocyte antigen 
HRP horseradish peroxidase 
HSA human serum albumin 
IFN-γ Interferon-gamma  
IL   Interleukin 
ITIM immunoreceptor tyrosine-based inhibion motive 
Kb kilobase  
kDa kiloDalton 
KIR killer cell Ig-like receptors 
KLR killer cell lectin-like receptors 
KLRK1 killer cell lectin-like receptor subfamily K, member 1 gene  
K-ras Kirsten rat sarcoma viral oncogene homolog protein 
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LAMP-1 lysosomal–associated membrane protein-1 
LH luteinizing hormone  
LIA luminescent immunoassay 
mAbs monoclonal antibodies 
MACS magnetic-activated cell sorting 
MDSC myeloid-derived suppressor cells 
mg milligram 
MHC major histocompatibility complex 
MIC-A -B MHC class I chain related -A -B 
min minute  
ml milliliters 
MMP matrix metalloproteinase 
MR mineralocorticoid receptor 
mRNA messenger RNA  
MULT-1 murine UL16-binding protein like transcript  
NAD nicotinamide adenine dinucleotide  
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
NCRs natural cytoxicity receptors 
ng  nanogram 
NK natural killer cells 
NKG2D natural killer group 2D 
NKT natural killer T cells 
nm nanometer 
NP-40 nonyl phenoxypolyethoxylethanol 
NY-ESO-1 cancer-testis antigen  
OD optical Density 
OSE ovarian surface epithelial 
OvCa ovarian cancer 
PBL peripheral blood lymphocytes 
PBMC peripheral blood monocytes 
PBS phosphate buffered Saline 
PBS-T phosphate-buffered saline   with 0.05% Tween20 
PCR polymerase chain reaction 
PD-1 programmed cell death 1 
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PE R-phycoerythrin  
PFA paraformaldehyde 
PG prostaglandins 
PMA phorbol 12-myristoyl 13-acetate 
PMSF phenylmethanesulfonylfluoride 
PTEN phosphatase and tensin homolog deleted on chromosome ten 
PVDF polyvinylidene Fluoride Membrane 
PVR polio virus receptor 
qRT-PCR   (semi-)quantitative real-time PCR 
RAE1 RNA export 1 homolog  
rpm revolutions per minute 
RPMI 1640    Roswell Park Memorial Institute cell culture medium 1640 
rRNA ribosomal ribonucleic acid 
RT-PCR   reverse transcriptase PCR 
SDS sodium dodecyl sulfate 
SDS-PAGE   Sodium dodecylsulfate (SDS) - Polyacrylamide Gel Electrophoresis  
SFI specific fluorescence intensity 
SHP Src-homology protein 
TAE Tris-acetate-EDTA 
TAM tumor-associated macrophages 
TBS Tris-buffered saline 
TEMED tetramethylethylenediamine 
TGF-β transforming growth factor-beta 
Th helper T cells 
TNF-α tumor necrosis factor-alpha 
Treg regulatory T cells 
ULBP UL16 binding protein 
UV ultraviolet 
V Volt 
VEGF vascular endothelial growth factor 
X g gravity 
γδ T gamma delta T cells 
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